var title_f37_61_38864="Moxifloxacin: Patient drug information";
var content_f37_61_38864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Moxifloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/45/9940?source=see_link\">",
"       Moxifloxacin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/51/2870?source=see_link\">",
"       Moxifloxacin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10880 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38864=[""].join("\n");
var outline_f37_61_38864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/45/9940?source=related_link\">",
"      Moxifloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/51/2870?source=related_link\">",
"      Moxifloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38865="Maltodextrin: Drug information";
var content_f37_61_38865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Maltodextrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carrington&reg; Oral Wound Rinse [OTC];",
"     </li>",
"     <li>",
"      Multidex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory, Locally Applied",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Management of pain due to oral lesions:",
"     </b>",
"     Carrington&reg; Oral Wound Rinse: 15 mL, swish or gargle for ~1 minute, 4 times/day or more if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Wound dressing:",
"     </b>",
"     Topical: Multidex&reg;: After debridement and irrigation of wound, apply and cover with a nonadherent, nonocclusive dressing. Apply",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     \" thick dressing over entire shallow wound. Completely fill in deep wounds with dressing. May be applied to moist or dry, infected or noninfected wounds. Change dressing once or twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multidex&reg;: 7.1 mL (7.1 mL); 14.2 mL (14.2 mL); 85.2 mL (85.2 mL) [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multidex&reg;: 6 g (6 g); 12 g (12 g); 25 g (25 g); 45 g (45 g) [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carrington&reg; Oral Wound Rinse: 23 g [contains aloe, fructose, phenylalanine, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multidex&reg;: 45 mL (45 mL) [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Treatment of infected or noninfected wounds",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Third-degree burns",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral: Avoid eating or drinking for 1 hour; products are not harmful if accidentally swallowed; notify healthcare provider if improvement is not seen within 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7731103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nessucar (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms a protective barrier over wound providing an environment which promotes tissue growth.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9818 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38865=[""].join("\n");
var outline_f37_61_38865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191204\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191200\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191201\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191190\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191183\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191191\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191193\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191186\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7731103\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276679\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191185\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38866="McBurney incision 1";
var content_f37_61_38866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    McBurney incision 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Incision through McBurney's point. (B) Fibers of external oblique separated. Internal oblique muscle split.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38866=[""].join("\n");
var outline_f37_61_38866=null;
var title_f37_61_38867="Agalsidase alfa: Drug information";
var content_f37_61_38867=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Agalsidase alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/44/9924?source=see_link\">",
"    see \"Agalsidase alfa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4803323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Replagal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4803327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4803359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fabry disease: I.V.: 0.2 mg/kg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4803358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fabry disease: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4803360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4803361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4803362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Replagal&trade;: 1 mg/1 mL (3.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11216688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4803363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 40 minutes using a dedicated I.V. line with filter. Do not infuse other agents through same I.V. line. Interrupt infusion in the presence of infusion-related reactions (eg, chills, flushing, dyspnea, rigors, tachycardia, urticaria). Infusion may be restarted after 5-10 minutes if symptoms subside or after administration of analgesics, antipyretics, antihistamines, and/or corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4803349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS. Do not mix or infuse with other products.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4803329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for Fabry disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4803319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Agalsidase alfa may be confused with agalsidase beta, alglucerase, alglucosidase alfa",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4803337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The most common and serious adverse reactions are infusion reactions (symptoms may include chills, dyspnea, facial flushing, fever, hypertension, nausea, rigors, tachycardia, urticaria, and vomiting).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Flushing (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (20%), headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Rigors (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: IgG antibody formation (55%), infusion-related reactions (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest tightness (7%), hypertension (4%), tachycardia (4%), chest pain (2%), edema (2%), peripheral coldness (2%), peripheral edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (9%), fatigue (9%), fatigue aggravated (7%), pain/discomfort (7%), hypersomnia (2%), hypoesthesia (2%), panic attack (2%), somnolence (2%), vertigo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Acne (9%), erythema (7%), mottled skin(4%), pruritus (4%), dry skin (2%), eczema (2%), rash (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (9%), dysgeusia (6%), diarrhea (4%), vomiting (4%), abdominal pain (2%), dyspepsia (2%), gastrointestinal upset (2%), stomach cramps (2%), stomach discomfort (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (6%), neuropathic pain (6%), tremor (4%), musculoskeletal discomfort (2%), back pain (2%), limb pain (2%), paraesthesia (2%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Lacrimation increased (2%), periorbital edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hoarseness (6%), throat tightness (6%), cough (4%), dyspnea (4%), nasopharyngitis (4%), pharyngitis (4%), nasal congestion (2%), snoring (2%), throat irritation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Feeling hot (4%), influenza-like syndrome(2%), parosmia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Chills, facial flushing, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4803332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to agalsidase alfa or any component of the formulation; concomitant use with chloroquine, amiodarone, monobenzone, or gentamicin (these agents have the potential to inhibit intracellular agalsidase alfa activity)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4803333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: The presence of IgG antibodies has been observed within 3 months from the onset of therapy in ~55% of treated patients. Approximately 60% of these patients are free of antibodies and &gt;80% demonstrate immune tolerance, based on reduced titers of antibody within 12-18 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reactions: Mild acute reactions (chills, facial flushing) are common and may occur during or within 1 hour after infusion. Severe reactions (nausea, pyrexia, rigors, tachycardia, urticaria, vomiting) are rare and usually occur within 2-4 months from the onset of therapy. Patients with a history of reactions may be premedicated with oral corticosteroids and antihistamines 1-3 hours prior to subsequent infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fabry disease: Common symptoms observed in this patient population may be confused with adverse reactions related to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4803343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4803330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. The benefits versus risks should be considered carefully before initiating agalsidase alfa therapy in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4803331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4803365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Globotriaosylceramide (Gb-3) levels (serum and urine)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Replagal (AU, BE, CH, CZ, DK, EE, ES, FI, IL, NO, NZ, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4803350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Agalsidase alfa is a recombinant form of the enzyme alpha-galactosidase-A, which catalyzes the hydrolysis of globotriaosylceramide (Gb-3) and other glycosphingolipids. These compounds may accumulate (over many years) within the tissues of patients with Fabry disease, leading to renal and cardiovascular complications. Agalsidase has been noted to reduce cellular levels of Gb-3 within the liver, heart, kidney, blood vessels, and in plasma.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4803352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17% of body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Plasma; via peptide hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~1.5-2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lidove O, Joly D, Barbey F, et al, &ldquo;Clinical Results of Enzyme Replacement Therapy in Fabry Disease: A Comprehensive Review of Literature&rdquo;,",
"      <i>",
"       Int J Clin Pract",
"      </i>",
"      , 2007, 61(2):293-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38867/abstract-text/17263716/pubmed\" id=\"17263716\" target=\"_blank\">",
"        17263716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ries M, Clarke JT, Whybra C, et al, &ldquo;Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(3):924-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38867/abstract-text/16950982/pubmed\" id=\"16950982\" target=\"_blank\">",
"        16950982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8515 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-C175512C90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38867=[""].join("\n");
var outline_f37_61_38867=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803323\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803327\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803359\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803358\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803360\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803361\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803362\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950004\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11216688\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803363\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803349\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803329\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803319\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803337\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803333\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298691\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803343\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803330\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803331\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803365\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539988\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803350\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803352\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/44/9924?source=related_link\">",
"      Agalsidase alfa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38868="Fenofibrate: Patient drug information";
var content_f37_61_38868=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fenofibrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     see \"Fenofibrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antara&reg;;",
"     </li>",
"     <li>",
"      Fenoglide&reg;;",
"     </li>",
"     <li>",
"      Lipofen&reg;;",
"     </li>",
"     <li>",
"      Lofibra&reg;;",
"     </li>",
"     <li>",
"      TriCor&reg;;",
"     </li>",
"     <li>",
"      Triglide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Feno-Micro&reg;;",
"     </li>",
"     <li>",
"      Apo-Feno-Super&reg;;",
"     </li>",
"     <li>",
"      Apo-Fenofibrate&reg;;",
"     </li>",
"     <li>",
"      Ava-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Dom-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Feno-Micro-200;",
"     </li>",
"     <li>",
"      Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Fenofibrate-S;",
"     </li>",
"     <li>",
"      Fenomax;",
"     </li>",
"     <li>",
"      Lipidil EZ&reg;;",
"     </li>",
"     <li>",
"      Lipidil Micro&reg;;",
"     </li>",
"     <li>",
"      Lipidil Supra&reg;;",
"     </li>",
"     <li>",
"      Mylan-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Novo-Fenofibrate Micronized;",
"     </li>",
"     <li>",
"      PHL-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      PMS-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      PRO-Feno-Super;",
"     </li>",
"     <li>",
"      Q-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      ratio-Fenofibrate MC;",
"     </li>",
"     <li>",
"      Riva-Fenofibrate Micro;",
"     </li>",
"     <li>",
"      Sandoz-Fenofibrate E;",
"     </li>",
"     <li>",
"      Sandoz-Fenofibrate S;",
"     </li>",
"     <li>",
"      Teva-Fenofibrate S",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop irritation of the pancreas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fenofibrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Gallbladder disease, very bad kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694412",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Antara&trade;, Triglide&trade;, TriCor&reg;: Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694851",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fenoglide&trade;, Lofibra&trade;, Lipofen&trade;: Take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Triglide&trade;: Do not take chipped or broken tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12466 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38868=[""].join("\n");
var outline_f37_61_38868=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011812\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011811\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011816\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011817\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011819\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011814\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011815\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011820\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011821\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=related_link\">",
"      Fenofibrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38869="Abacavir and lamivudine: Patient drug information";
var content_f37_61_38869=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Abacavir and lamivudine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     see \"Abacavir and lamivudine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/3/17462?source=see_link\">",
"     see \"Abacavir and lamivudine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epzicom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2519848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kivexa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems and a change in acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. Pregnancy, obesity, and/or longer therapy may raise this chance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the warning card and carry it with you at all times. It tells the signs to watch for in case an allergy happens.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to abacavir, lamivudine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped because you have an allergy to it, do not restart it. It may not be safe to restart this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped for any other reason, do not restart it without talking to the doctor. It could be very risky to restart on your own.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug changes for HIV infection, make sure to ask your doctor about hepatitis B care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritated pancreas may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic reaction (fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, sore throat, cough, trouble breathing, or flu-like signs). Stop this drug and talk with your doctor right away!",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In HIV care, this drug is most often taken with 2 other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11315 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38869=[""].join("\n");
var outline_f37_61_38869=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2519848\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017210\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017212\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017211\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017216\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017217\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017219\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017214\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017215\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017220\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017221\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=related_link\">",
"      Abacavir and lamivudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/3/17462?source=related_link\">",
"      Abacavir and lamivudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38870="Heart biopsy with nest of amastigotes";
var content_f37_61_38870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart biopsy with nest of amastigotes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient was a female from Bolivia who had a transplant for end-stage Chagas cardiomyopathy. The photo is of the explanted heart.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vimon Seriburi and Umadevi Katta.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38870=[""].join("\n");
var outline_f37_61_38870=null;
var title_f37_61_38871="Multiple endocrine neoplasia type 1: Treatment";
var content_f37_61_38871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multiple endocrine neoplasia type 1: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Andrew Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38871/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/61/38871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder classically characterized by predisposition to tumors of the parathyroid glands (which occur in nearly all patients by age 50 years), anterior pituitary, and pancreatic islet cells (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"mobipreview.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ). MEN1 also includes a predisposition to gastrinomas in the duodenum, carcinoids, adrenal adenomas, angiofibromas, and lipomas (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ). The tumors are generally benign, but malignancy of some carcinoid, islet cell, and gastrointestinal tract tumors are important causes of mortality in MEN1.",
"   </p>",
"   <p>",
"    This topic will review the treatment of MEN1. The classification, genetics, clinical manifestations, and diagnosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARATHYROID ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple parathyroid adenomas causing primary hyperparathyroidism are the most common manifestation of MEN1, with over 90 percent penetrance by age 40 to 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiple gland involvement is common in these patients and, given sufficient time, perhaps universal. Patients with classical MEN1 are at high risk of recurrent hyperparathyroidism after apparently successful subtotal parathyroidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the biochemical diagnosis of primary hyperparathyroidism is confirmed in a patient with known or presumed MEN1, the indications for surgical intervention are similar to those in patients with sporadic adenomas causing primary hyperparathyroidism. These include symptomatic or marked hypercalcemia, nephrolithiasis, and evidence of bone disease such as diminished bone density or fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/2\">",
"     2",
"    </a>",
"    ]. Bone density of the lumbar spine and hip can improve after parathyroidectomy in patients with hyperparathyroidism associated with MEN1, as it does in patients with sporadic hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional indication for parathyroidectomy in patients with MEN1 is the presence of severe peptic ulcer disease or other symptoms caused by a gastrinoma (the Zollinger-Ellison syndrome) that are difficult to control with medications. Hypercalcemia typically worsens hypergastrinemia, and parathyroidectomy may markedly reduce gastrin secretion in patients with a gastrinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The typical success of pharmacologic therapy for hypergastrinemia makes this a rare indication for operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management of asymptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery or no therapy can be acceptable alternatives for patients with MEN1 who have asymptomatic or minimally symptomatic hyperparathyroidism, as they are for patients with sporadic hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .) Whether early treatment of hyperparathyroidism reduces mortality or morbidity in patients with MEN1 is not known, but many clinicians lean toward surgery in young patients because of their long life expectancy (and years at risk for developing bone disease). On the other hand, other clinicians defer surgery as long as possible, in the hope that fewer operations for recurrent hyperparathyroidism (which may be more difficult than the initial surgery) will be needed during the patient's lifetime.",
"   </p>",
"   <p>",
"    The clinician's threshold for recommending surgery for patients with asymptomatic hyperparathyroidism bears importantly on the decision to screen asymptomatic persons at risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link&amp;anchor=H24809205#H24809205\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening of family members in MEN1 kindreds'",
"    </a>",
"    .) Such decisions must also take into account the level of surgical expertise available at one's institution, an important consideration because of the likelihood of recurrent hyperparathyroidism and need for another operation in the future.",
"   </p>",
"   <p>",
"    We tend to defer surgery in MEN1 patients with asymptomatic hyperparathyroidism who also lack specific indications for surgery, such as diminished bone density. In such patients, periodic monitoring should be performed for disease progression and development of indications for surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of primary hyperparathyroidism\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do, however, tend to recommend surgery for asymptomatic patients with reduced bone density for the reasons mentioned above, and therefore find it reasonable to regularly screen individuals with MEN1 for biochemical hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with MEN1 have multiple parathyroid tumors so bilateral exploration of previously unoperated patients should be planned, regardless of the outcome of preoperative localization studies, such as ultrasonography, sestamibi imaging, or chest CT. However, the surgeon may find these studies to be anatomically helpful and may therefore order them. We recommend these studies before reoperation in patients with recurrent or persistent disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies, persistent disease is more common among patients who were treated with less than subtotal parathyroidectomy (42 versus 0 to 12 percent in patients with less than three versus three or more glands resected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Thus, for patients with MEN1 and indications for parathyroidectomy, we recommend subtotal (three and one-half gland) parathyroidectomy rather than removal of fewer glands.",
"   </p>",
"   <p>",
"    Patients with classical MEN1 are at high risk of recurrent hyperparathyroidism after apparently successful subtotal parathyroidectomy; this finding reflects the strong and seemingly inexorable proliferative drive in parathyroid cells in this disorder. One report from the National Institutes of Health, for example, found a recurrence rate of greater than 50 percent at 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/1\">",
"     1",
"    </a>",
"    ]; in another report, the recurrence rate was 67 percent at eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral neck exploration should be performed to attempt to find all glands in patients with known or suspected MEN1. Experts disagree, however, about the optimum extent of the subtotal parathyroidectomy procedure. Some favor a more extensive procedure to reduce the risk of recurrent disease, while others favor a less extensive procedure to decrease the risk of hypoparathyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most commonly, initial surgery involves removal of three and one-half parathyroid glands (or all but one-half gland, if supernumerary glands are found), together with thymectomy. Surgery is repeated if hypercalcemia and specific indications recur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more aggressive initial surgical approach involves complete parathyroidectomy and placement of a small parathyroid autograft in the muscles of the forearm or neck [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/12-15\">",
"       12-15",
"      </a>",
"      ]. Recurrent hyperparathyroidism due to growth of the autograft can then be treated by graft removal under local anesthesia. If, however, the autograft does not function, the patient may have permanent hypoparathyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials comparing the two approaches. In a review of 18 reports of 2 to 73 patients with MEN1 followed for 4 to 12 years after subtotal parathyroidectomy (three and one-half glands resected) with or without cervical thymectomy, persistent hyperparathyroidism was reported in 0 to 33 percent, recurrent hyperparathyroidism in 0 to 36 percent, and persistent hypoparathyroidism in 0 to 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/6\">",
"     6",
"    </a>",
"    ]. In the same review, there were 10 reports of 4 to 36 patients with MEN1 who had complete parathyroidectomy with cervical thymectomy and autologous placement of a small parathyroid autograft. After a mean follow-up of 6 to 10 years, persistent hyperparathyroidism was reported in 0 to 3 percent, recurrent hyperparathyroidism in 0 to 55 percent, and hypoparathyroidism in 0 to 46 percent. In these observational studies, the more aggressive approach was associated with lower rates of persistent hyperparathyroidism but higher rates of hypoparathyroidism.",
"   </p>",
"   <p>",
"    When performed by a surgeon who has extensive experience in either approach, as surgery for MEN1 patients should be, results are good and complication rates are low. In such instances, the preference of the experienced surgeon should be followed.",
"   </p>",
"   <p>",
"    While cervically-accessible thymectomy during initial parathyroidectomy in MEN1 is generally recommended, its role continues to be discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The clearest rationale for thymectomy relates to the substantial frequency with which intrathymic parathyroid tissue is found as a present or future source of pathologic PTH production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/16\">",
"     16",
"    </a>",
"    ]. Since only part of the thymus is accessible cervically, this measure will not completely prevent the future development of thymic carcinoid, a rare but often-aggressive tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/17\">",
"     17",
"    </a>",
"    ]. Still, we think the potential benefit of preventing some thymic carcinoids outweighs the potential risk of this procedure in the hands of an expert surgeon, so we generally favor thymectomy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4445841\">",
"    <span class=\"h2\">",
"     Medical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcimimetic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    ) activate the calcium-sensing receptor in the parathyroid gland, thereby inhibiting PTH secretion. Although not typically used in the United States for the treatment of sporadic primary hyperparathyroidism, cinacalcet reduces serum calcium in the majority of affected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of primary hyperparathyroidism\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/23/26998?source=see_link\">",
"     Cinacalcet",
"    </a>",
"    probably also decreases the serum calcium concentration in patients with primary hyperparathyroidism due to MEN1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/18\">",
"     18",
"    </a>",
"    ], although the data are sparse. In a case report of a patient with MEN1 and recurrent hyperparathyroidism five years after parathyroidectomy, treatment with cinacalcet reduced serum calcium and PTH levels to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/19\">",
"     19",
"    </a>",
"    ]. During one year of treatment, levels remained normal. Thus, cinacalcet may be beneficial for patients with MEN1 and recurrent symptomatic primary hyperparathyroidism who are not candidates for or refuse repeated surgical procedures. However, there are no long-term data evaluating the effect of cinacalcet on clinically important outcomes (eg, bone density, fracture, nephrolithiasis, mortality) in patients with MEN1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PITUITARY ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of patients with MEN1 have clinically apparent pituitary adenomas. The characteristics of these adenomas in terms of hormonal activity and other features are similar to those in patients with sporadic pituitary adenomas. The most common pituitary adenoma in MEN1 is a lactotroph adenoma, but all other types of adenomas can occur (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"mobipreview.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ). Multiple pituitary tumors are rarely present in MEN1. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with MEN1 who have pituitary adenomas should be treated in the same way as patients with sporadic adenomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8857?source=see_link\">",
"     \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=see_link\">",
"     \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7322?source=see_link\">",
"     \"Treatment of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PANCREATIC ISLET CELL/GASTROINTESTINAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the efficacy of therapy for hyperparathyroidism and pituitary tumors in patients in MEN1, malignant pancreatic islet cell and gastrointestinal tumors are the primary life-threatening components of the disorder. Endocrine cell tumors at these sites become clinically apparent in approximately one-third of patients with MEN1. However, subclinical involvement is more common; anatomic or intensive biochemical studies reveal evidence of pancreatic tumors in up to 80 percent of patients with MEN1.",
"   </p>",
"   <p>",
"    The most common cause of symptoms is the Zollinger-Ellison (gastrinoma) syndrome. About 40 percent of patients with MEN1 have either the Zollinger-Ellison syndrome or asymptomatic elevation in serum gastrin concentrations. Symptomatic insulinomas are also fairly common, but tumors that are symptomatic due to secretion of vasoactive-intestinal polypeptide, glucagon or pancreatic polypeptide are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Zollinger-Ellison syndrome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2290283\">",
"    <span class=\"h3\">",
"     General therapeutic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to treat the Zollinger-Ellison syndrome surgically in patients with MEN1 have involved resection of palpable tumors or partial pancreatectomy, but historically this approach uniformly failed to cure the hypersecretion of gastrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The recognition that patients with MEN1 often have small, multifocal tumors in the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/22\">",
"     22",
"    </a>",
"    ] is consistent with these failures, and has led to reexamination of the role of surgery. Some surgeons now regularly operate on MEN1 patients with the Zollinger-Ellison syndrome that persists after correction of hyperparathyroidism, or if imaged tumors in the pancreaticoduodenal region exceed a certain size threshold (eg, 2 or 3 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The current approach includes duodenotomy, often preceded by endoscopic ultrasound or accompanied by intraoperative ultrasonography, and subtotal pancreatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], or even more aggressive resections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/29\">",
"     29",
"    </a>",
"    ], and can be subject to modification based upon the individual situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the impressive efficacy of proton pump blockers in controlling symptoms, the primary benefit to be sought from surgery is a decrease in mortality from metastatic gastrinoma. While results of modern surgical approaches seem promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/26,28,30-32\">",
"     26,28,30-32",
"    </a>",
"    ], longer follow-up studies are needed because the likelihood of developing hepatic metastases and death may be low even in unoperated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/28\">",
"     28",
"    </a>",
"    ]. Currently, no definitive evidence exists that surgery decreases the mortality of the disease in MEN1 or the likelihood that clinically important metastases will develop, although a nonrandomized study suggests that it may [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2290290\">",
"    <span class=\"h3\">",
"     Pharmacologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy for patients with a MEN1-associated gastrinoma is administration of a proton pump inhibitor such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .) When given once or twice daily these drugs effectively inhibit acid secretion and relieve acid-peptic symptoms in these patients for prolonged periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/25\">",
"     25",
"    </a>",
"    ]. A nine-year prospective study of the safety and efficacy of omeprazole revealed no tachyphylaxis or important toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2290309\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of whether or not to recommend duodenal-pancreatic surgery in patients with MEN1 who have pharmacologically controllable Zollinger-Ellison syndrome and no other clinically evident hormonal excess syndrome or imaged tumors is an especially difficult one. Because clinical outcome data are not definitive, we extensively discuss potential advantages and risks of both options with the patient. While we do not strongly advocate for surgery, we do not discourage a patient who wishes to have surgery for MEN1-associated Zollinger-Ellison syndrome, as long as the individual recognizes that solid proof of improved mortality is lacking and that the surgeon is experienced and knowledgeable. Furthermore, if such a patient requires abdominal surgery for another reason (such as insulinoma), it seems appropriate to include duodenotomy in the procedure.",
"   </p>",
"   <p>",
"    For patients with pharmacologically-controlled Zollinger-Ellison who do not have surgery, we monitor symptoms. Imaging studies (computed",
"    <span class=\"nowrap\">",
"     tomography/magnetic",
"    </span>",
"    resonance imaging) are performed only as clinically indicated. Clinicians who favor pancreaticoduodenal surgery when a tumor exceeds a certain size threshold may choose to image more regularly. However, data favoring the use of such specific triggers in improving outcomes (eg, preventing metastases, mortality) are very limited. Further, in MEN1, the imaged tumor(s) may not actually be the source of the excess gastrin.",
"   </p>",
"   <p>",
"    The best course for patients with hepatic metastases is unclear. Possibilities include surgical debulking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic artery chemoembolization, chemotherapy with streptozotocin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    . Although octreotide has not been demonstrated to prolong survival, it may delay tumor progression; the impact on symptoms is unpredictable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=see_link&amp;anchor=H8#H8\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\", section on 'Somatostatin analogs'",
"    </a>",
"    .) Novel therapeutic approaches are being sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/34\">",
"     34",
"    </a>",
"    ]. Given the indolent behavior of metastases in many patients and the relative lack of efficacy of most treatments, we tend to observe only and defer surgery or chemotherapy until the situation dictates that some intervention be attempted. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 10 percent of patients with MEN1 have an insulinoma (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ). Approximately 4 to 10 percent of patients with insulinomas have MEN1, and in most of them the MEN1 is known or suspected. Treatment is complicated by the possible presence of multiple insulinomas, the likelihood that preoperative or intraoperative localization techniques may miss small tumors, and the continuing risk for pancreatic tumors after surgery. As a result, some experienced surgeons recommend local excision of any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/35\">",
"     35",
"    </a>",
"    ]. This approach differs from that in patients with sporadic insulinomas, who typically have a solitary tumor and in whom localization and local excision alone are usually successful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15104854\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of patients with MEN1 is uncertain. In a retrospective review of 233 patients with MEN1 treated at the Mayo Clinic, the overall 20-year survival of MEN1 patients was significantly lower than that of an age, gender, and geographically matched-population (64 versus 81 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/36\">",
"     36",
"    </a>",
"    ]. Among those in whom a cause of death could be reliably obtained (60 of 69 patients), 28 percent died of causes related to MEN1, most commonly metastatic islet cell tumors. Similarly, in European populations, the mean ages at death for patients with MEN1 was significantly lower than in the average population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/37\">",
"     37",
"    </a>",
"    ]. Compared with nonaffected patients, those with thymic tumors and duodenopancreatic neuroendocrine or nonfunctioning tumors had a higher risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/38\">",
"     38",
"    </a>",
"    ]. Because effective treatment is available for hyperparathyroidism and pituitary disease in MEN1, the malignant potential of pancreatic endocrine tumors and thymic carcinoids are the primary life-threatening manifestations of MEN1. These tumors are often present at initial assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38871/abstract/17,39\">",
"     17,39",
"    </a>",
"    ]. Whether earlier detection through radiographic screening improves mortality remains uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1181458\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for parathyroidectomy in patients with MEN1 are similar to those in patients with sporadic adenomas causing primary hyperparathyroidism and include symptomatic hypercalcemia, nephrolithiasis, and evidence of bone disease, such as diminished bone density or fracture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of primary hyperparathyroidism\", section on 'Candidates for surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with MEN1 and indications for parathyroidectomy, we recommend subtotal (three and one-half gland) parathyroidectomy rather than removal of fewer glands (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We generally favor including cervical thymectomy in this setting. Also acceptable is removal of all four glands with cervical thymectomy and autologous transplantation of parathyroid tissue. The choice of procedure depends upon the expertise of the parathyroid surgeon. Surgery should only be performed by surgeons highly experienced in parathyroid surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pituitary adenomas in patients with MEN1 should be treated in the same way as sporadic pituitary adenomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=see_link\">",
"       \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7322?source=see_link\">",
"       \"Treatment of acromegaly\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=see_link\">",
"       \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8857?source=see_link\">",
"       \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Zollinger-Ellison syndrome as part of the MEN1 syndrome should be treated primarily by proton pump therapy to limit the clinical manifestations and complications of peptic ulcer disease. If this treatment controls symptoms, the role of duodenal-pancreatic surgery to prevent metastatic disease is uncertain and controversial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Zollinger-Ellison syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=see_link&amp;anchor=H2#H2\">",
"       \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\", section on 'Medical management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgery is indicated for patients with MEN1 and insulinoma. Because patients with MEN1 often have additional pancreatic tumors that may include other insulinomas, local excision of any tumors in the head of the pancreas plus a distal subtotal pancreatectomy is frequently performed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insulinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link\">",
"       \"Insulinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of metastatic gastroenteropancreatic neuroendocrine tumors is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/1\">",
"      Rizzoli, R, Green, J, Marx, SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type 1. Am J Med 1985; 78:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/2\">",
"      Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/3\">",
"      Coutinho FL, Louren&ccedil;o DM Jr, Toledo RA, et al. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf) 2010; 72:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/4\">",
"      Mai HD, Sanowski RA. Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy. Gastrointest Endosc 1992; 38:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/5\">",
"      Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/6\">",
"      Tonelli F, Marcucci T, Giudici F, et al. Surgical approach in hereditary hyperparathyroidism. Endocr J 2009; 56:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/7\">",
"      St&aring;lberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg 2009; 33:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/8\">",
"      Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 2011; 35:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/9\">",
"      Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 1998; 133:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/10\">",
"      Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 2005; 257:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/11\">",
"      O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993; 114:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/12\">",
"      Hellman P, Skogseid B, Juhlin C, et al. Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1. World J Surg 1992; 16:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/13\">",
"      Baumann DS, Wells SA Jr. Parathyroid autotransplantation. Surgery 1993; 113:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/14\">",
"      Cohen MS, Dilley WG, Wells SA Jr, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 2005; 138:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/15\">",
"      Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 2007; 246:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/16\">",
"      Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008; 144:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/17\">",
"      Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009; 33:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/18\">",
"      Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010; 2010:906163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/19\">",
"      Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/20\">",
"      Akerstr&ouml;m G, Johansson H, Grama D. Surgical treatment of endocrine pancreatic lesions in MEN-1. Acta Oncol 1991; 30:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/21\">",
"      Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989; 106:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/22\">",
"      Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/23\">",
"      Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg 2006; 244:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/24\">",
"      Gauger PG, Doherty GM, Broome JT, et al. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 2009; 146:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/25\">",
"      Libutti SK, Alexander HR Jr. Gastrinoma: sporadic and familial disease. Surg Oncol Clin N Am 2006; 15:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/26\">",
"      Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/27\">",
"      Fraker DL, Alexander HR. The surgical approach to endocrine tumors of the pancreas. Semin Gastrointest Dis 1995; 6:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/28\">",
"      Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005; 89:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/29\">",
"      Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/30\">",
"      Hausman MS Jr, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004; 136:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/31\">",
"      Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003; 58:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/32\">",
"      Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011; 17:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/33\">",
"      Metz DC, Strader DB, Orbuch M, et al. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/34\">",
"      Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/35\">",
"      Demeure MJ, Klonoff DC, Karam JH, et al. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991; 110:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/36\">",
"      Dean PG, van Heerden JA, Farley DR, et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000; 24:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/37\">",
"      Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003; 149:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/38\">",
"      Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38871/abstract/39\">",
"      Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009; 33:1208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2026 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38871=[""].join("\n");
var outline_f37_61_38871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1181458\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARATHYROID ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management of asymptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4445841\">",
"      Medical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PITUITARY ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PANCREATIC ISLET CELL/GASTROINTESTINAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Zollinger-Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2290283\">",
"      - General therapeutic considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2290290\">",
"      - Pharmacologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2290309\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15104854\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1181458\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/40/20108\" title=\"table 1\">",
"      MEN syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/56/37772\" title=\"table 2\">",
"      Expressions of MEN1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7322?source=related_link\">",
"      Treatment of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8857?source=related_link\">",
"      Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38872="Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma";
var content_f37_61_38872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38872/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/61/38872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoplasmacytic lymphoma (LPL, previously termed lymphoplasmacytoid lymphoma) is an uncommon mature B cell lymphoma usually involving the bone marrow and, less commonly, the spleen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Waldenstr&ouml;m macroglobulinemia is a clinicopathologic entity associated with an IgM monoclonal gammopathy in the blood that is virtually always a manifestation of LPL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathobiology, clinical presentation, pathologic features, diagnosis, and differential diagnosis of LPL will be reviewed here. The diagnosis, treatment, and prognosis of Waldenstr&ouml;m macroglobulinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPL accounts for approximately 1 percent of hematologic malignancies in the United States and Western Europe with an incidence of approximately 8.3 cases per million persons per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The vast majority of patients are Caucasian with other ethnic groups accounting for approximately 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/7\">",
"     7",
"    </a>",
"    ]. The median age is 65 years and 50 to 60 percent of patients are male.",
"   </p>",
"   <p>",
"    The majority of patients with LPL have a circulating monoclonal IgM that often leads to a hyperviscosity syndrome known as Waldenstr&ouml;m macroglobulinemia (WM). Although LPL appears to be a sporadic disease in the majority of cases, a familial predisposition is present in some cases. The epidemiology of LPL and WM is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some cases of LPL demonstrate a mixed (type II) cryoglobulinemia and concurrent hepatitis C virus (HCV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Some such cases may in fact be better classified as splenic marginal zone lymphoma, which has also been associated with hepatitis C infection and may be accompanied by paraproteinemia. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Marginal zone lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198194648\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postulated normal counterpart to the malignant cell in LPL is a peripheral B lymphocyte stimulated to differentiate to a plasma cell, possibly corresponding to the primary immune response to antigen, or to a post germinal center cell that has undergone somatic mutation but not heavy chain class switch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/11\">",
"     11",
"    </a>",
"    ]. Gene expression profiling studies reveal a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of LPL is incompletely understood. One report found that 13 of 14 tumors studied had evidence of somatic hypermutation of the immunoglobulin heavy chain gene, without intraclonal variation, suggesting that the cell of origin is a post-germinal center B cell that has already undergone affinity maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/13\">",
"     13",
"    </a>",
"    ]. Several other studies have found that chromosomal rearrangements involving the IgH locus are uncommon in LPL, likely because the cell of origin is post-germinal center. However, deletions of 6q21 have been identified in 40 to 60 percent of patients with Waldenstr&ouml;m macroglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/14\">",
"     14",
"    </a>",
"    ]. The target gene(s) at this site have not yet been identified, but this is a common site of chromosome loss in many B cell lymphoma variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9628277\">",
"    <span class=\"h2\">",
"     MYD88 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;MYD88 is a molecule that plays a part in toll-like receptor and interleukin-1 receptor signaling leading to enhanced B cell survival. An activating point mutation of MYD88 (MYD88 L265P) has been implicated in the pathogenesis of LPL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, genome-wide massively parallel sequencing of bone marrow LPL cells and paired normal cells from the same patient identified MYD88 L265P mutations in 10 of 10 patients with LPL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/16\">",
"       16",
"      </a>",
"      ]. Sequencing of this gene in additional patients revealed the MYD88 L265P mutation in 49 of 54 patients with WM and 3 of 3 patients with non-IgM-secreting LPL. This mutation was absent in the paired normal tissue samples and in B cells from 10 healthy donors and 10 patients with multiple myeloma. The MYD88 L265P mutation was also significantly less common in patients with marginal zone lymphoma (7 percent), or IgM monoclonal gammopathy of undetermined significance (10 percent).",
"     </li>",
"     <li>",
"      A subsequent study reported the MYD88 L265P mutation in 18 of 27 cases of",
"      <span class=\"nowrap\">",
"       WM/LPL",
"      </span>",
"      (67 percent), 2 of 28 cases of extranodal marginal zone lymphoma (7 percent), 2 of 53 cases of splenic marginal zone lymphoma (4 percent), and none of 11 cases of nodal marginal zone lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these findings suggest that MYD88 mutations have a central role in the pathogenesis of LPL, possibly because they promote the activation of transcription factors of the NF-kB family, which have been linked to the growth and survival of both normal and neoplastic B cells. Although highly associated with LPL, MYD88 mutations are not entirely specific; they have also been reported in a subset of diffuse large B cell lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/18\">",
"     18",
"    </a>",
"    ] and, as noted above, also occur in a subset of other plasma cell dyscrasias (eg, IgM MGUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/19\">",
"     19",
"    </a>",
"    ] and low-grade B cell lymphoproliferative disorders.",
"    <em>",
"    </em>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with LPL is varied and can include symptoms related to tumor infiltration (lymphadenopathy, organomegaly, cytopenias) or monoclonal protein production (hyperviscosity, neuropathy). Approximately one-third of patients are asymptomatic at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/20\">",
"     20",
"    </a>",
"    ]. The most common presenting features include weakness and fatigue, often due to anemia. Up to one-quarter of patients display systemic B symptoms (ie, fever, night sweats, weight loss) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Systemic complaints (B symptoms)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphadenopathy, hepatomegaly, and splenomegaly are each seen in approximately 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/21\">",
"     21",
"    </a>",
"    ]. More than 70 percent of patients have stage IV disease by virtue of bone marrow involvement at the time of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). Approximately 70 percent have an International prognostic index (IPI) of 2 or 3 (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients demonstrate a monoclonal immunoglobulin protein (gammopathy) in their serum on serum protein electrophoresis or immunofixation, but the presence of a gammopathy is not necessary for the diagnosis of LPL. A monoclonal serum IgM (",
"    <a class=\"graphic graphic_figure graphicRef61928 \" href=\"mobipreview.htm?34/2/34862\">",
"     figure 1",
"    </a>",
"    ) is the most common subtype and confers a diagnosis of the clinical syndrome Waldenstr&ouml;m macroglobulinemia (WM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/22\">",
"     22",
"    </a>",
"    ]. Less commonly, the tumor produces other immunoglobulins, a combination of immunoglobulins (ie, IgM and IgG), mixed cryoglobulins, or gamma heavy chains. As mentioned earlier, most cases with mixed cryoglobulinemia are related to concurrent hepatitis C virus (HCV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor cells of a small percent of otherwise typical LPL secrete IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    express it on their surface membrane. In one series, these patients had a median age of 70 years, with significant lymphocytosis and splenomegaly, strong positivity for CD79b, a 60 percent incidence of trisomy 12, and a non-aggressive clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other cases of paraproteinemia, the serum total protein level and erythrocyte sedimentation rate are commonly elevated and laboratory artifacts may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 40 percent of patients have mild anemia at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/20\">",
"     20",
"    </a>",
"    ]. Severe anemia, neutropenia, and thrombocytopenia are much less common. Beta-2-microglobulin can be elevated. The serum lactate dehydrogenase is typically normal.",
"   </p>",
"   <p>",
"    Circulating monoclonal protein may interfere with laboratory tests resulting in spurious results. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Laboratory artifacts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPL is typically composed of small B cells, plasmacytoid lymphocytes, and plasma cells, involving the bone marrow. Less commonly, it can involve the lymph nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spleen. Circulating tumor cells are infrequently seen in the peripheral blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow infiltrate may be diffuse, nodular, or interstitial with or without paratrabecular aggregates. The infiltrate contains small lymphocytes, plasma cells and plasmacytoid cells in variable numbers admixed with frequent reactive mast cells. Variable numbers of immunoblasts may be admixed (",
"    <a class=\"graphic graphic_picture graphicRef66365 \" href=\"mobipreview.htm?28/2/28708\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52862 \" href=\"mobipreview.htm?4/32/4614\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Accumulation of cytoplasmic immunoglobulin (IgM) in some cells results in inclusions with periodic acid Schiff (PAS) staining known as Russell bodies (cytoplasmic) or Dutcher bodies (pseudonuclear) depending on their intracellular location (",
"    <a class=\"graphic graphic_picture graphicRef67576 \" href=\"mobipreview.htm?17/54/18272\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81311 \" href=\"mobipreview.htm?14/18/14627\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Extracellular deposits of immunoglobulin can take the form of amorphous masses or crystals, sometimes associated with a foreign-body giant cells reaction. Such deposits are usually discovered incidentally and of no clinical importance. Amyloid deposition may occur, but is much less common in LPL than in myeloma and other plasma cell neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Lymph node",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node architecture is frequently preserved, but can be effaced by a diffuse, interstitial infiltrate comprised of small lymphocytes, plasma cells, and plasmacytoid cells. Some cases may also contain large, immunoblast-like cells. Sinuses are often open, and may contain histiocytes reacting to secreted periodic acid Schiff (PAS) positive immunoglobulin (",
"    <a class=\"graphic graphic_picture graphicRef73998 \" href=\"mobipreview.htm?23/31/24054\">",
"     picture 5",
"    </a>",
"    ). Typical characteristics include Dutcher and Russell bodies, mast cells, and hemosiderin-laden macrophages. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bone marrow'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Of importance, proliferation centers, the hallmark of chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic leukemia, are absent as is the presence of the paler-appearing marginal zone differentiation seen in marginal zone lymphoma. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Chronic lymphocytic leukemia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Marginal zone lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the red and white pulp of the spleen may be infiltrated. The pattern is usually diffuse, without a distinct marginal zone or nodularity in the red pulp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating malignant cells often have a plasmacytoid appearance (ie, resembling a plasma cell). Such cells are typically oval with abundant basophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef63684 \" href=\"mobipreview.htm?19/27/19888\">",
"     picture 6",
"    </a>",
"    ). The nucleus is round and eccentrically located with a perinuclear hof, or cytoplasmic clearing. The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPL cells express high levels of surface immunoglobulin (sIg), usually of IgM type; surface IgD is usually lacking. Cases in which IgG and IgA are expressed have been described.",
"   </p>",
"   <p>",
"    These tumors express pan B cell antigens (CD19, CD20, CD22, CD79a). The plasma cells express CD138. The majority express lymphocyte function associated antigen 1 (LFA-1). Adhesion molecules expressed on approximately half of these tumors include L-selectin, ICAM-1, CD44 and CD11c. The cells are variable in their expression of CD43; CD25 or CD11c may be faintly positive in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Most, but not all cases lack expression of CD5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/28\">",
"     28",
"    </a>",
"    ]. CD10, CD103, and CD23 are usually not expressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no chromosomal abnormalities that are specific for LPL. Immunoglobulin heavy and light chain genes are rearranged, and variable (V) region genes show somatic mutations, suggesting that these cells arise from a population of B cells that have undergone antigen&ndash;driven selection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/29-33\">",
"     29-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deletion of chromosome 6q21 is the most common genetic abnormality and is found in more than half of cases based in the bone marrow, but less frequently in lymph node-based disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/34\">",
"     34",
"    </a>",
"    ]. Less common genetic changes include trisomy 3, trisomy 8, and trisomy 4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/1\">",
"     1",
"    </a>",
"    ]. The translocation t(9;14)(p13;q32) originally reported in a number of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/35-39\">",
"     35-39",
"    </a>",
"    ], was subsequently found to be rare in LPL and not specific for this entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of LPL is made by pathologic evaluation of involved tissue, usually bone marrow or lymph node. A combination of histology and immunophenotypic findings is used to exclude other small B cell lymphoid neoplasms with plasmacytic differentiation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten percent or more of the biopsy sample must demonstrate infiltration by small lymphocytes, plasmacytoid lymphocytes, and plasma cells, with variable numbers of admixed immunoblasts. In the marrow there is a characteristic (but not pathognomonic) hyperplasia of mast cells that accompanies the neoplastic infiltrate. Proliferation centers (pathognomonic of",
"      <span class=\"nowrap\">",
"       CLL/SLL)",
"      </span>",
"      and paler-appearing marginal zone type differentiation (seen in marginal zone lymphoma) are absent.",
"     </li>",
"     <li>",
"      This infiltrate should express a typical immunophenotype (eg, surface IgM+,",
"      <span class=\"nowrap\">",
"       CD5+/-,",
"      </span>",
"      CD10-, CD19+, CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, CD103-, CD138-). The plasmacytic component will be CD138+, CD38+ and CD45- or dim.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variations from the typical immunophenotype may occur, but the goal is to satisfactorily exclude other lymphoproliferative disorders. Further evaluation of a patient with LPL includes a serum protein electrophoresis (SPEP) to evaluate for the presence of a monoclonal immunoglobulin (Ig) \"spike\" associated with the clinicopathologic entity Waldenstr&ouml;m macroglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for LPL includes other small B cell lymphoid neoplasms with plasmacytic differentiation (",
"    <a class=\"graphic graphic_table graphicRef69760 \" href=\"mobipreview.htm?3/16/3341\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both LPL and chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic lymphoma",
"    <span class=\"nowrap\">",
"     (CLL/SLL)",
"    </span>",
"    are lymphoproliferative disorders of small cells, which have an indolent course. Characteristics useful in distinguishing LPL from CLL include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral blood involvement in LPL is usually less prominent than in CLL; circulating malignant cells in LPL often have a plasmacytoid appearance whereas those in CLL resemble mature lymphocytes mixed with variable numbers of so-called prolymphocytes, larger cells with single distinct nucleoli.",
"     </li>",
"     <li>",
"      The bone marrow infiltrate of LPL is usually less extensive than that of CLL, and, unlike CLL, contains a mixture of small lymphocytes, plasma cells, plasmacytoid cells, and lacks prolymphocytes and proliferation centers. Frequent reactive mast cells are also characteristic of LPL, but are sometimes seen in CLL as well.",
"     </li>",
"     <li>",
"      Lymph node involvement in LPL lacks proliferation centers that are pathognomonic of",
"      <span class=\"nowrap\">",
"       CLL/SLL.",
"      </span>",
"     </li>",
"     <li>",
"      The immunophenotype of LPL is notable for the lack of CD23, the presence of strong staining for surface IgM and CD20, and the presence of cytoplasmic Ig. Most, but not all cases of LPL lack expression of CD5, which is expressed in CLL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link\">",
"       \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is a plasma cell neoplasm characterized by malignant plasma cells in the bone marrow and the presence of a monoclonal protein in the serum or urine. Symptoms related to hyperviscosity are rare. In contrast to LPL, classical multiple myeloma with an IgM paraprotein is extremely rare, comprising less than 1 percent of patients.",
"   </p>",
"   <p>",
"    Often, LPL can be distinguished from multiple myeloma by the absence of CD56 and the presence of a substantial small lymphocytic component that expresses a clonal surface immunoglobulin. In difficult cases, one may have to rely on the differences in clinical presentation to exclude multiple myeloma. For example, a diagnosis of IgM multiple myeloma is preferred over a diagnosis of LPL if bone lesions are present. Symptoms of hyperviscosity, and the presence of lymphadenopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly favor a diagnosis of LPL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL) is usually comprised of monomorphous small to medium-sized B lymphocytes with irregular nuclei. MCL tumor cells are typically CD5+ and CD23-; the vast majority overexpress cyclin D1. The t(11;14) translocation, which is not specific for MCL, is seen in a little over half of patients on conventional cytogenetics, but in a much higher percentage of patients screened with FISH. This translocation is seen in some cases of multiple myeloma, but not in LPL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Cyclin D1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both LPL and marginal zone lymphoma (MZL) are tumors that contain a polymorphous infiltrate of small cells. The immunophenotype is also similar with MZL cells expressing B cell markers CD19, CD20, and CD22, and not CD5, CD10, and CD23. Chromosomal abnormalities, usually trisomy 3 or t(11;18), are found in most cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike LPL, MZL often has a population of cells with abundant pale cytoplasm (so-called monocytoid B cells) that is indicative of marginal zone-type differentiation. In addition, patients with MZL are more likely to demonstrate mixed cryoglobulinemia and hepatitis C infection. However, given the similar histology and immunophenotype, it can be difficult to differentiate between LPL and MZL. In some cases a more general diagnosis of \"small B cell lymphoma with plasmacytic differentiation\" may be the most accurate classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both LPL and follicular lymphoma (FL) can demonstrate a nodular growth pattern of small B lymphocytes. In contrast to FL, LPL is CD10 negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of LPL is indolent; in some European series it has been reported to be more aggressive than typical chronic lymphocytic",
"    <span class=\"nowrap\">",
"     leukemia/small",
"    </span>",
"    lymphocytic leukemia",
"    <span class=\"nowrap\">",
"     (CLL/SLL),",
"    </span>",
"    with median survival in the range of five to seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, in the REAL clinical study, five-year overall survival (58 percent) and failure-free survival (25 percent) were identical to that of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38872/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with LPL have a circulating monoclonal IgM consistent with the diagnosis of Waldenstr&ouml;m macroglobulinemia (WM). Prognostic factors for WM are discussed in more detail separately.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37626?source=see_link\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoplasmacytic lymphoma (LPL) is an uncommon mature B cell lymphoma usually involving the bone marrow and, less commonly, the spleen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymph nodes. Waldenstr&ouml;m macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating LPL in the bone marrow with an IgM monoclonal gammopathy in the blood. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical presentation of LPL is varied and can include symptoms related to tumor infiltration (lymphadenopathy, organomegaly, cytopenias) or monoclonal protein production (hyperviscosity, neuropathy). Approximately one-third of patients are asymptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients demonstrate a monoclonal gammopathy, but a gammopathy is not necessary for the diagnosis. The most common subtype is monoclonal IgM (",
"      <a class=\"graphic graphic_figure graphicRef61928 \" href=\"mobipreview.htm?34/2/34862\">",
"       figure 1",
"      </a>",
"      ), which confers a diagnosis of WM. Less commonly the tumor produces other immunoglobulins, a combination of immunoglobulins, mixed cryoglobulins, or gamma heavy chains. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of LPL is made by pathologic evaluation of involved tissue, usually bone marrow or lymph node. A combination of histology and immunophenotypic findings is used to exclude other small B cell lymphoid neoplasms with plasmacytic differentiation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ten percent or more of the biopsy sample must demonstrate infiltration by small lymphocytes, plasmacytoid lymphocytes, and plasma cells, with variable numbers of admixed immunoblasts. In the marrow there is a characteristic (but not pathognomonic) hyperplasia of mast cells that accompanies the neoplastic infiltrate. Proliferation centers (pathognomonic of",
"      <span class=\"nowrap\">",
"       CLL/SLL)",
"      </span>",
"      and cells with abundant pale cytoplasm showing marginal zone type differentiation (so-called monocytoid B cells, seen in marginal zone lymphoma) are absent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      This infiltrate should express a typical immunophenotype (eg, surface IgM+,",
"      <span class=\"nowrap\">",
"       CD5+/-,",
"      </span>",
"      CD10-, CD19+, CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, CD103-, CD138-). The plasmacytic component will be CD138+, CD38+ and CD45- or dim. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variations from the typical histology and immunophenotype may occur, but the goal is to satisfactorily exclude other lymphoproliferative disorders (",
"      <a class=\"graphic graphic_table graphicRef69760 \" href=\"mobipreview.htm?3/16/3341\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation of a patient with LPL includes a serum protein electrophoresis (SPEP) to evaluate for the presence of a monoclonal immunoglobulin (Ig) \"spike\" associated with WM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/3\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/4\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/5\">",
"      A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/6\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/7\">",
"      Groves FD, Travis LB, Devesa SS, et al. Waldenstr&ouml;m's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998; 82:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/8\">",
"      Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/9\">",
"      Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/10\">",
"      Krishnan C, Cupp JS, Arber DA, Faix JD. Lymphoplasmacytic lymphoma arising in the setting of hepatitis C and mixed cryoglobulinemia. J Clin Oncol 2007; 25:4312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/11\">",
"      Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/12\">",
"      Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/13\">",
"      Walsh SH, Laurell A, Sundstr&ouml;m G, et al. Lymphoplasmacytic lymphoma/Waldenstr&ouml;m's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. Leuk Res 2005; 29:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/14\">",
"      Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstr&ouml;m macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/15\">",
"      Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991; 77:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/16\">",
"      Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr&ouml;m's macroglobulinemia. N Engl J Med 2012; 367:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/17\">",
"      Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr&ouml;m macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/18\">",
"      Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/19\">",
"      Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012; 367:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/20\">",
"      Garc&iacute;a-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstr&ouml;m macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/21\">",
"      Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 2008; 67:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/22\">",
"      Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/23\">",
"      Garand R, Sahota SS, Avet-Loiseau H, et al. IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. Br J Haematol 2000; 109:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/24\">",
"      Zukerberg LR, Medeiros LJ, Ferry JA, Harris NL. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993; 100:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/25\">",
"      Stein H, Lennert K, Feller AC, Mason DY. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/26\">",
"      Harris NL, Bhan AK. B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation. Hum Pathol 1985; 16:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/27\">",
"      Lennert, K, Tamm, I, Wacker, H-H. Histopathology and immunocytochemistry of lymph node biopsies in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1991; (Suppl):157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/28\">",
"      Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstr&ouml;m macroglobulinemia. Am J Clin Pathol 2005; 124:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/29\">",
"      Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstr&ouml;m's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995; 85:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/30\">",
"      Crouzier R, Martin T, Pasquali JL. Monoclonal IgM rheumatoid factor secreted by CD5-negative B cells during mixed cryoglobulinemia. Evidence for somatic mutations and intraclonal diversity of the expressed VH region gene. J Immunol 1995; 154:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/31\">",
"      Sahota SS, Garand R, Bataille R, et al. VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. Blood 1998; 91:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/32\">",
"      Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994; 83:3647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/33\">",
"      Kriangkum J, Taylor BJ, Treon SP, et al. Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res 2007; 13:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/34\">",
"      Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstr&ouml;m macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 2001; 116:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/35\">",
"      Offit K, Parsa NZ, Jhanwar SC, et al. Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. Genes Chromosomes Cancer 1993; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/36\">",
"      Hamada T, Yonetani N, Ueda C, et al. Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998; 102:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/37\">",
"      Morrison AM, J&auml;ger U, Chott A, et al. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood 1998; 92:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/38\">",
"      Iida S, Rao PH, Ueda R, et al. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma 1999; 34:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/39\">",
"      Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/40\">",
"      Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 2004; 35:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/41\">",
"      Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept. Adv Anat Pathol 2005; 12:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/42\">",
"      Andrieux J, Fert-Ferrer S, Copin MC, et al. Three new cases of non-Hodgkin lymphoma with t(9;14)(p13;q32). Cancer Genet Cytogenet 2003; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/43\">",
"      Brittinger G, Bartels H, Common H, et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 1984; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38872/abstract/44\">",
"      Engelhard, M, Brittinger, G, Heinz, R, et al. Chronic lymphocytic leukemia (B-CLL) and immunocytoma (LP-IC): Clinical and prognostic relevance of this distinction. Leuk Lymphoma 1991; Suppl:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4768 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38872=[""].join("\n");
var outline_f37_61_38872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198194648\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9628277\">",
"      MYD88 mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gammopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Lymph node",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Spleen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4768|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/2/34862\" title=\"figure 1\">",
"      SPEP in WM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4768|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/2/28708\" title=\"picture 1\">",
"      Lymphoplasmacytic cells in WM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/32/4614\" title=\"picture 2\">",
"      LPL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/54/18272\" title=\"picture 3\">",
"      Dutcher body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/18/14627\" title=\"picture 4\">",
"      Dutcher body PAS stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/31/24054\" title=\"picture 5\">",
"      Lymphoplasmacytic node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/27/19888\" title=\"picture 6\">",
"      Plasma cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/16/3341\" title=\"table 3\">",
"      Ddx LPL path",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38873="Carboplatin: Drug information";
var content_f37_61_38873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carboplatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/18/40228?source=see_link\">",
"    see \"Carboplatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/10/43174?source=see_link\">",
"    see \"Carboplatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carboplatin Injection;",
"     </li>",
"     <li>",
"      Carboplatin Injection - LIQ IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Platinum Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Doses for adults are commonly calculated by the target AUC using the Calvert formula, where",
"     <b>",
"      Total dose (mg) = Target AUC x (GFR + 25)",
"     </b>",
"     . If estimating glomerular filtration rate (GFR) instead of a measured GFR, the Food and Drug Administration (FDA) recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced:",
"     </b>",
"     I.V.: 360 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (as a single agent)",
"     <b>",
"      or",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (in combination  with cyclophosphamide)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 4-6 (single agent; in previously-treated patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing for advanced ovarian cancer:",
"     </i>",
"     I.V.: Target AUC 5-7.5 every 3 weeks (in combination with paclitaxel) (Ozols, 2003; Parmar, 2003)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with docetaxel) (Vasey, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with gemcitabine and paclitaxel) (Hainsworth, 2005)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with gemcitabine) (Bamias, 2006)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with paclitaxel) (Vaughn, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 6 every 3 weeks (in combination with trastuzumab and paclitaxel) (Robert, 2006)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with trastuzumab and docetaxel) (Pegram, 2004; Valero, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer, recurrent or metastatic (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with paclitaxel) (Pectasides, 2009)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5-6 every 4 weeks (in combination with paclitaxel) (Tinker, 2005)",
"     <b>",
"      or",
"     </b>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 28 days (as a single agent) (Weiss, 1990)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with paclitaxel) (Pectasides, 2008)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 2 on days 1, 8, and 15 every 28 days (in combination with paclitaxel) (Secord, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 2 on days 1, 8, 15, 22, and 29 for 1 cycle (in combination with paclitaxel) (van Meerten, 2006)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with paclitaxel) (El-Rayes, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with cetuximab) (Chan, 2005)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with cetuximab and fluorouracil) (Vermorken, 2008)",
"     <b>",
"      or",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4 weeks (in combination with fluorouracil) (Forastiere, 1992)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with paclitaxel) (Clark, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin's lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 (maximum dose 800 mg) for 2 cycles (in combination with ifosfamide and etoposide) (Moskowitz, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with pemetrexed) (Castagneto, 2008; Ceresoli, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Melanoma, advanced or metastatic (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 2 days on 1, 8, and 15 every 4 weeks (in combination with paclitaxel) (Rao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin&rsquo;s lymphomas, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 (maximum dose 800 mg) per cycle for 3 cycles (in combination with rituximab, ifosfamide and etoposide) (Kewalramani, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 6 every 3-4 weeks (in combination with paclitaxel) (Ramalingam, 2008; Schiller, 2002; Strauss, 2008)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with bevacizumab and paclitaxel) (Sandler, 2006)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with pemetrexed) (Gronberg, 2009)",
"     <b>",
"      or",
"     </b>",
"     in combination with radiation therapy and paclitaxel (Belani, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target AUC 6 every 3 weeks for 2 cycles",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target AUC 6 every 3 weeks for 2 cycles; then target AUC 2 weekly for 7 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target AUC 2 every week for 7 weeks; then target AUC 6 every 3 weeks for 2 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sarcomas: Ewing&rsquo;s sarcoma, osteosarcoma (unlabeled uses):",
"     </b>",
"     I.V.: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days every 21 days (in combination with ifosfamide and etoposide) (van Winkle, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 6 every 3 weeks (in combination with etoposide) (Skarlos, 2001)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with irinotecan) (Hermes, 2008)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 28 days (in combination with irinotecan) (Schmittel, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 7 as a one-time dose (Oliver, 2011)",
"     <b>",
"      or",
"     </b>",
"     700 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days beginning 5 days prior to peripheral stem cell infusion (in combination with etoposide) for 2 cycles (Einhorn, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thymic malignancies (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 5 every 3 weeks (in combination with paclitaxel) (Lemma, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unknown primary adenocarcinoma (unlabeled use):",
"     </b>",
"     I.V.: Target AUC 6 every 3 weeks (in combination with paclitaxel) (Briasoulis, 2000)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with docetaxel) (Greco, 2000)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 6 every 3 weeks (in combination with paclitaxel and etoposide) (Hainsworth, 2006)",
"     <b>",
"      or",
"     </b>",
"     Target AUC 5 every 3 weeks (in combination with paclitaxel and gemcitabine) (Greco, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in obesity:",
"     </b>",
"     Dosing based on GFR should be considered in obese patients (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F146217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/10/43174?source=see_link\">",
"      see \"Carboplatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Glioma (unlabeled use):",
"     </b>",
"     I.V.: 175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 4 weeks every 6 weeks, with a 2-week recovery period between courses (in combination with vincristine) (Packer, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma, localized and unresectable (unlabeled use):",
"     </b>",
"     I.V.: Children &ge;10 kg: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day days 1, 2, and 3 every 21 days for 2 cycles (in combination with etoposide for 2 cycles then followed by cyclophosphamide, doxorubicin and vincristine) (Rubie, 1998)",
"     <b>",
"      or",
"     </b>",
"     Children &lt;1 year: 6.6 mg/kg/day days 1, 2, and 3 (in combination with etoposide for 2 cycles, then followed by cyclophosphamide, doxorubicin, and vincristine) (Rubie, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sarcomas: Ewing&rsquo;s sarcoma, osteosarcoma (unlabeled uses):",
"     </b>",
"     I.V.: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days every 21 days (in combination with ifosfamide and etoposide) (van Winkle, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The Calvert formula should be used to calculate dosing for elderly patients. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F146194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose determination with Calvert formula uses GFR and, therefore, inherently adjusts for renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The manufacturer&rsquo;s labeling recommends the following dosage adjustment guidelines for single-agent therapy: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     41-59 mL/minute: Initiate at 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and adjust subsequent doses based on bone marrow toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     16-40 mL/minute: Initiate at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and adjust subsequent doses based on bone marrow toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Baseline Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;15 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following dosage adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     GFR &lt;50 mL/minute: Use Calvert formula incorporating patient&rsquo;s GFR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis, peritoneal dialysis, continuous renal replacement therapy (CRRT): Use Calvert formula incorporating patient&rsquo;s GFR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults (",
"     <b>",
"      Note:",
"     </b>",
"     For dosing based on",
"     <b>",
"      mg/m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     GFR &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     GFR 10-50 mL/minute: Administer 50% of the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     GFR &lt;10 mL/minute: Administer 25% of the dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hemodialysis: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 25% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Janus, 2010:  Hemodialysis: Carboplatin dose (mg) = Target AUC x 25; administer on a nondialysis day, hemodialysis should occur between 12-24 hours after carboplatin dose",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F146195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, carboplatin undergoes minimal hepatic metabolism therefore dosage adjustment may not be needed.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3272713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Platelets &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (5 mL, 15 mL, 45 mL, 60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually infused over 15-60 minutes, although some protocols may require infusions up to 24 hours. When administered as a part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence recommendation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Needles or I.V. administration sets that contain aluminum should not be used in the preparation or administration of carboplatin; aluminum can react with carboplatin resulting in precipitate formation and loss of potency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F146245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, anidulafungin, aztreonam, caspofungin, cefepime, cladribine, doripenem, doxorubicin liposomal, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, linezolid, melphalan, micafungin, ondansetron, oxaliplatin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, propofol, sargramostim, teniposide, thiotepa, topotecan, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial treatment of advanced ovarian cancer in combination with other established chemotherapy agents; palliative treatment of recurrent ovarian cancer after prior chemotherapy, including cisplatin-based treatment",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F146235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder cancer, breast cancer (metastatic), central nervous system tumors, cervical cancer (recurrent or metastatic), endometrial cancer,  esophageal cancer, head and neck cancer, Hodgkin's lymphoma (relapsed or refractory), malignant pleural mesothelioma, melanoma (advanced or metastatic), merkel cell carcinoma, neuroendocrine tumors (adrenal gland and carcinoid tumors), non-Hodgkin&rsquo;s lymphomas (relapsed or refractory), nonsmall cell lung cancer, retinoblastoma, sarcomas (Ewing&rsquo;s sarcoma and osteosarcoma), small-cell lung cancer, testicular cancer, thymic malignancies, unknown primary adenocarcinoma, and as a conditioning regimen prior to hematopoietic stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F146248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CARBOplatin may be confused with CISplatin, oxaliplatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paraplatin&reg; may be confused with Platinol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Percentages reported with single-agent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia (29% to 47%), hypomagnesemia (29% to 43%), hypocalcemia(22% to 31%), hypokalemia (20% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (65% to 81%), abdominal pain (17%), nausea (without vomiting: 10% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (dose related and dose limiting; nadir at ~21 days with single-agent therapy), anemia (71% to 90%; grades 3/4: 21%), leukopenia (85%; grades 3/4: 15% to 26%), neutropenia (67%; grades 3/4: 16% to 21%), thrombocytopenia (62%; grades 3/4: 25% to 35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (24% to 37%), AST increased (15% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine clearance decreased (27%), BUN increased (14% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity/allergic reaction (2% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6%), diarrhea (6%), stomatitis/mucositis (1%), taste dysgeusia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (5%), hemorrhagic complications (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbance (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ototoxicity (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction, bronchospasm, cardiac failure, cerebrovascular accident, dehydration, embolism, erythema, hemolytic anemia (acute), hemolytic uremic syndrome (HUS), hyper-/hypotension, injection site reactions (pain, redness, swelling), limb ischemia (acute), necrosis (associated with extravasation), neutropenic fever, pruritus, rash, secondary malignancies, urticaria, vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of severe allergic reaction to carboplatin, cisplatin, other platinum-containing formulations, mannitol, or any component of the formulation; should not be used in patients with severe bone marrow depression or significant bleeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression, which may be severe, is dose related; may result in infection (due to neutropenia) or bleeding (due to thrombocytopenia); anemia may require blood transfusion.",
"     </b>",
"     Reduce dosage in patients with bone marrow suppression; cycles should be delayed until WBC and platelet counts have recovered. Patients who have received prior myelosuppressive therapy and patients with renal dysfunction are at increased risk for bone marrow suppression. Anemia is cumulative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylactic-like reactions have been reported with carboplatin; may occur within minutes of administration. Epinephrine, corticosteroids and antihistamines have been used to treat symptoms.",
"     </b>",
"     The risk of allergic reactions (including anaphylaxis) is increased in patients previously exposed to platinum therapy. Skin testing and desensitization protocols have been reported (Confina-Cohen, 2005; Lee, 2004; Markman, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver function abnormalities: High doses (&gt;4 times the recommended dose) have resulted in severe abnormalities of liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Although peripheral neuropathy occurs infrequently, the incidence of peripheral neuropathy is increased patients &gt;65 years of age and those who have previously received cisplatin treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity: Ototoxicity may occur when administered concomitantly with aminoglycosides. Clinically significant hearing loss has been reported to occur in pediatric patients when therapy was administered at higher than recommended doses in combination with other ototoxic agents (eg, aminoglycosides). In a study of children receiving carboplatin for the treatment of retinoblastoma, those &lt;6 months of age at treatment initiation were more likely to experience ototoxicity; long-term audiology monitoring is recommended (Qaddoumi, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Limited potential for nephrotoxicity unless administered concomitantly with aminoglycosides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss: Loss of vision (usually reversible within weeks of discontinuing) has been reported with higher than recommended doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vomiting:",
"     <b>",
"      [U.S. Boxed Warning]: Vomiting may occur.",
"     </b>",
"     May be severe in patients who have received prior emetogenic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; patients with renal dysfunction are at increased risk for bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Taxane derivatives: When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before the platinum derivatives (carboplatin, cisplatin) to limit myelosuppression and to enhance efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). Patients &gt;65 years of age are more likely to develop thrombocytopenia (severe) and peripheral neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosing with Calvert formula: When calculating the carboplatin dose using the Calvert formula and an estimated glomerular filtration rate (GFR), the laboratory method used to measure serum creatinine may impact dosing.  Compared to other methods, standardized isotope dilution mass spectrometry (IDMS) may underestimate serum creatinine values in patients with low creatinine values (eg, &le;0.7 mg/dL) and may overestimate GFR  in patients with normal renal function. This may result in higher calculated carboplatin doses and increased toxicities. If using IDMS, the Food and Drug Administration (FDA) recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): CARBOplatin may increase the serum concentration of Bexarotene (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May enhance the adverse/toxic effect of CARBOplatin. Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F146185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and teratogenicity have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3272444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for toxicity in nursing infants, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (CARBOplatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $9.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/15 mL (15 mL): $25.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg/45 mL (45 mL): $78.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/60 mL (60 mL): $118.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CARBOplatin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $258.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F146165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (with differential and platelet count), serum electrolytes, serum creatinine and BUN, creatinine clearance, liver function tests; audiology evaluations (children &lt;6 months of age)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actoplatin (ID);",
"     </li>",
"     <li>",
"      Bagotanilo (MX);",
"     </li>",
"     <li>",
"      Balidon (CO);",
"     </li>",
"     <li>",
"      Biovinate (PH);",
"     </li>",
"     <li>",
"      Biplatinex (VE);",
"     </li>",
"     <li>",
"      Blastocarb (CN);",
"     </li>",
"     <li>",
"      Blastocarb RU (MX);",
"     </li>",
"     <li>",
"      Bobei (CL);",
"     </li>",
"     <li>",
"      Carboplat (AR, DE, MX);",
"     </li>",
"     <li>",
"      Carboplatin (AU, DK, IL, NO, NZ);",
"     </li>",
"     <li>",
"      Carboplatin a (PT);",
"     </li>",
"     <li>",
"      Carboplatin Abic (TH);",
"     </li>",
"     <li>",
"      Carboplatin DBL (MY);",
"     </li>",
"     <li>",
"      Carboplatin dbl (PT);",
"     </li>",
"     <li>",
"      Carboplatin &ldquo;Delta West&rdquo; (HR);",
"     </li>",
"     <li>",
"      Carboplatin-David Bull (LU);",
"     </li>",
"     <li>",
"      Carboplatin-Medac (LU);",
"     </li>",
"     <li>",
"      Carboplatin-Teva (HU);",
"     </li>",
"     <li>",
"      Carboplatino (EC, PE);",
"     </li>",
"     <li>",
"      Carboplatinum Cytosafe-Delta West (LU);",
"     </li>",
"     <li>",
"      Carbosin (BE, GR, NO, PH);",
"     </li>",
"     <li>",
"      Carbosin Lundbeck (FI);",
"     </li>",
"     <li>",
"      Carbotec (MX);",
"     </li>",
"     <li>",
"      Carbotinol (PH);",
"     </li>",
"     <li>",
"      Carplan (KP);",
"     </li>",
"     <li>",
"      Cobalmin (PE);",
"     </li>",
"     <li>",
"      Cycloplatin (CZ, HU, PL);",
"     </li>",
"     <li>",
"      Delta West Carboplatin (ID, PH);",
"     </li>",
"     <li>",
"      Kemocarb (PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Naproplat (PH);",
"     </li>",
"     <li>",
"      Neoplatin (KP);",
"     </li>",
"     <li>",
"      Neoplatine (BR);",
"     </li>",
"     <li>",
"      Omilipis (AR, PY);",
"     </li>",
"     <li>",
"      Oncocarb (PE);",
"     </li>",
"     <li>",
"      Oncocarbin (IN);",
"     </li>",
"     <li>",
"      P&amp;U Carboplatin (ZA);",
"     </li>",
"     <li>",
"      Paraplatin (AT, BE, BG, BR, CH, EC, EE, EG, ES, FI, FR, GB, HK, HN, HR, HU, IE, IT, LU, NL, PH, PT, RU, SE, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Pharmaplatin (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 16 L (based on a dose of 300-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); into liver, kidney, skin, and tumor tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Carboplatin: 0%; Platinum (from carboplatin): Irreversibly binds to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic to aquated and hydroxylated compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Carboplatin: 2.6-5.9 hours (based on a dose of 300-500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); Platinum (from carboplatin): &ge;5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% as carboplatin within 24 hours; 3% to 5% as platinum within 1-4 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bamias A, Moulopoulos LA, Koutras A, et al, &ldquo;The Combination of Gemcitabine and Carboplatin as First-Line Treatment in Patients With Advanced Urothelial Carcinoma. A Phase II Study of the Hellenic Cooperative Oncology Group,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(2):297-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16342065 /pubmed\" id=\"16342065 \" target=\"_blank\">",
"        16342065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Belani CP, Choy H, Bonomi P, et al, &ldquo;Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(25):5883-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16087941/pubmed\" id=\"16087941\" target=\"_blank\">",
"        16087941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benaji B, Dine T, Luyckx M, et al, &ldquo;Stability and Compatibility of Cisplatin and Carboplatin With PVC Infusion Bags,&rdquo;",
"      <i>",
"       J Clin Pharm Ther",
"      </i>",
"      , 1994, 19(2):95-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/8071399/pubmed\" id=\"8071399\" target=\"_blank\">",
"        8071399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briasoulis E, Kalofonos H, Bafaloukos D, et al, &ldquo;Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(17):3101-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/10963638/pubmed\" id=\"10963638\" target=\"_blank\">",
"        10963638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calvert AH, Newell DR, Grumbell LA, et al, &ldquo;Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(11):1748-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/2681557/pubmed\" id=\"2681557\" target=\"_blank\">",
"        2681557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castagneto B, Botta M, Aitini E, et al, &ldquo;Phase II Study of Pemetrexed in Combination With Carboplatin in Patients With Malignant Pleural Mesothelioma (MPM),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(2):370-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18156144/pubmed\" id=\"18156144\" target=\"_blank\">",
"        18156144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ceresoli GL, Zucali PA, Favaretto AG, et al, &ldquo;Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(9):1443-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16549838/pubmed\" id=\"16549838\" target=\"_blank\">",
"        16549838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan AT, Hsu MM, Goh BC, et al, &ldquo;Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3568-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15809453/pubmed\" id=\"15809453\" target=\"_blank\">",
"        15809453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheung Y-W, Cradock JC, Vishnuvajjala BR, et al, \"Stability of Cisplatin, Iproplatin, Carboplatin, and Tetraplatin in Commonly Used Intravenous Solutions,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1987, 44:124-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/3548341/pubmed\" id=\"3548341\" target=\"_blank\">",
"        3548341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark JI, Hofmeister C, Choudhury A, et al, &ldquo;Phase II Evaluation of Paclitaxel in Combination With Carboplatin in Advanced Head and Neck Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 92(9):2334-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11745288/pubmed\" id=\"11745288\" target=\"_blank\">",
"        11745288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Confino-Cohen R, Fishman A, Altaras M, et al, &ldquo;Successful Carboplatin Desensitization in Patients With Proven Carboplatin Allergy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 104(3):640-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15977213/pubmed\" id=\"15977213\" target=\"_blank\">",
"        15977213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donahue A, McCune JS, Faucette S, et al, &ldquo;Measured Versus Estimated Glomerular Filtration Rate in the Calvert Equation: Influence on Carboplatin Dosing,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2001, 47(5):373-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11391850/pubmed\" id=\"11391850\" target=\"_blank\">",
"        11391850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doz F, Neuenschwander S, Plantaz D, et al, &ldquo;Etoposide and Carboplatin in Extraocular Retinoblastoma: A Study by the Societe Francaise d'Oncologie Pediatrique,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(4):902-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/7707117/pubmed\" id=\"7707117\" target=\"_blank\">",
"        7707117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einhorn LH, Williams SD, Chamness A, et al, &ldquo;High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(4):340-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/17652649/pubmed\" id=\"17652649\" target=\"_blank\">",
"        17652649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      El-Rayes BF, Shields A, Zalupski M, et al, &ldquo;A Phase II Study of Carboplatin and Paclitaxel in Esophageal Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(6):960-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15151955/pubmed\" id=\"15151955\" target=\"_blank\">",
"        15151955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Sheinfeld J, Bajorin DF, et al, &ldquo;TI-CE High Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors:  Results and Prognostic Factor Analysis,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(10):1706-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/20194867/pubmed\" id=\"20194867\" target=\"_blank\">",
"        20194867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forastiere AA, Metch B, Schuller DE, et al, &ldquo;Randomized Comparison of Cisplatin Plus Fluorouracil and Carboplatin Plus Fluorouracil Versus Methotrexate in Advanced Squamous-Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1992, 10(8):1245-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/1634913/pubmed\" id=\"1634913\" target=\"_blank\">",
"        1634913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman DL, Himelstein B, Shields CL, et al, \"Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(1):12-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/10623688/pubmed\" id=\"10623688\" target=\"_blank\">",
"        10623688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Burris HA 3rd, Erland JB, et al, &ldquo;Carcinoma of Unknown Primary Site,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2000, 89(12):2655-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11135228/pubmed\" id=\"11135228\" target=\"_blank\">",
"        11135228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Burris HA 3rd, Litchy S, et al, &ldquo;Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(6):1651-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11896116/pubmed\" id=\"11896116\" target=\"_blank\">",
"        11896116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Erland JB, Morrissey LH, et al, &ldquo;Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11(2):211-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/10761758/pubmed\" id=\"10761758\" target=\"_blank\">",
"        10761758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gronberg BH, Bremnes RM, Flotten O, et al, &ldquo;Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer, &rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/19433683/pubmed\" id=\"19433683\" target=\"_blank\">",
"        19433683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hainsworth JD, Meluch AA, Litchy S, et al, &ldquo;Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 103(11):2298-303",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15856431 /pubmed\" id=\"15856431 \" target=\"_blank\">",
"        15856431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hainsworth JD, Spigel DR, Litchy S, et al, &ldquo;Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(22):3548-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16877720/pubmed\" id=\"16877720\" target=\"_blank\">",
"        16877720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hermes A, Bergman B, Bremnes R, et al, &ldquo;Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(26):4261-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18779613/pubmed\" id=\"18779613\" target=\"_blank\">",
"        18779613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kewalramani T, Zelenetz AD, Nimer SD, et al, &ldquo;Rituximab and ICE as Second-Line Therapy before Autologous Stem Cell Transplantation for Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(10):3684-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/14739217 /pubmed\" id=\"14739217 \" target=\"_blank\">",
"        14739217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kondagunta GV, Bacik J, Sheinfeld J, et al, &ldquo;Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(1):85-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/17194908/pubmed\" id=\"17194908\" target=\"_blank\">",
"        17194908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee CW, Matulonis UA, and Castells MC, &ldquo;Carboplatin Hypersensitivity: A 6-h 12-Step Protocol Effective in 35 Desensitizations in Patients With Gynecological Malignancies and Mast Cell/IgE-Mediated Reactions,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 95(2):370-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15491759/pubmed\" id=\"15491759\" target=\"_blank\">",
"        15491759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lemma GL, Loehrer PJ, Lee JW, et al, &ldquo;A Phase II Study of Carboplatin Plus Paclitaxel in Advanced Thymoma or Thymic Carcinoma: E1C99,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15s):8018 [abstract 8018 from 2000 annual ASCO meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markman M, Kennedy A, Webster K, et al, &ldquo;Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(7):1901-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11283121/pubmed\" id=\"11283121\" target=\"_blank\">",
"        11283121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markman M, Zanotti K, Peterson G, et al, &ldquo;Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(24):4611-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/14673050/pubmed\" id=\"14673050\" target=\"_blank\">",
"        14673050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Modlin J and Mancini R, &ldquo;Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart,&rdquo;",
"      <i>",
"       J Hematol Oncol",
"      </i>",
"      , 2011, 1(1):17-25. Available at file://issuu.com/theoncologypharmacist/docs/jhop_march2011?mode=embed&amp;layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Fdark%2Flayout.xml&amp;showFlipBtn=true",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moskowitz CH, Nimer SD, Zelenetz AD, et al, &ldquo;A 2-Step Comprehensive High-Dose Chemoradiotherapy Second-Line Program for Relapsed and Refractory Hodgkin Disease: Analysis by Intent to Treat and Development of a Prognostic Model,&rdquo; B",
"      <i>",
"       lood",
"      </i>",
"      , 2001, 97(3):616-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11157476/pubmed\" id=\"11157476\" target=\"_blank\">",
"        11157476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oliver RT, Mason MD, Mead GM, et al, &ldquo;Radiotherapy versus Single-Dose Carboplatin in Adjuvant Treatment for Stage I Seminoma: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9482):293-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16039331/pubmed\" id=\"16039331\" target=\"_blank\">",
"        16039331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oliver RT, Mead GM, Rustin GJ, et al, &ldquo;Randomized Trial of Carboplatin versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214),",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(8):957-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/21282539/pubmed\" id=\"21282539\" target=\"_blank\">",
"        21282539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ozols RF, Bundy BN, Greer BE, et al, &ldquo;Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(17):3194-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12860964/pubmed\" id=\"12860964\" target=\"_blank\">",
"        12860964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer RJ, Ater J, Allen J, et al, &ldquo;Carboplatin and Vincristine Chemotherapy for Children With Newly Diagnosed Progressive Low-Grade Gliomas,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 1997, 86(5):747-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/9126887/pubmed\" id=\"9126887\" target=\"_blank\">",
"        9126887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parmar MK, Ledermann JA, Colombo N, et al, &ldquo;Paclitaxel Plus Platinum-Based Chemotherapy Versus Conventional Platinum-Based Chemotherapy in Women With Relapsed Ovarian Cancer: The ICON4/AGO-OVAR-2.2 Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9375):2099-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12826431/pubmed\" id=\"12826431\" target=\"_blank\">",
"        12826431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Fountzilas G, Papaxoinis G, et al, &ldquo;Carboplatin and Paclitaxel in Metastatic or Recurrent Cervical Cancer,&rdquo;",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2009, 19(4):777-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/19509587/pubmed\" id=\"19509587\" target=\"_blank\">",
"        19509587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Xiros N, Papaxoinis G, et al, &ldquo;Carboplatin and Paclitaxel in Advanced or Metastatic Endometrial Cancer,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2008, 109(2):250-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18299146/pubmed\" id=\"18299146\" target=\"_blank\">",
"        18299146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pegram MD, Pienkowski T, Northfelt DW, et al, &ldquo;Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(10):759-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15150304/pubmed\" id=\"15150304\" target=\"_blank\">",
"        15150304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pillot GA, Read WL, Hennenfent KL, et al, &ldquo;A Phase II Study of Irinotecan and Carboplatin in Advanced Non-Small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2006, 1(9):972-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/17409981/pubmed\" id=\"17409981\" target=\"_blank\">",
"        17409981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poulsen M, Rischin D, Walpole, et al, &ldquo;High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study --TROG 96:07,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(23):4371-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/14645427/pubmed\" id=\"14645427\" target=\"_blank\">",
"        14645427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poulsen M, Walpole E, Harvey J, et al, &ldquo;Weekly Carboplatin Reduces Tocixity During Synchronous Chemoradiotherapy for Merkel Cell Carcinoma of Skin,\"",
"      <i>",
"       Int J Radiat Oncol Biol Phys",
"      </i>",
"      , 2008, 72(4):1070-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18707820/pubmed\" id=\"18707820\" target=\"_blank\">",
"        18707820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaddoumi I, Bass JK, Wu J, et al, &ldquo;Carboplatin-Associated Ototoxicity in Children With Retinoblastoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(10):1034-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/22370329/pubmed\" id=\"22370329\" target=\"_blank\">",
"        22370329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramalingam S, Perry MC, La Rocca RV, et al, &ldquo;Comparison of Outcomes for Elderly Patients Treated With Weekly Paclitaxel in Combination With Carboplatin versus the Standard 3-Weekly Paclitaxel and Carboplatin for Advanced Nonsmall Cell Lung Cancer,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(3):542-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18512224/pubmed\" id=\"18512224\" target=\"_blank\">",
"        18512224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rao D, Holtan SG, Ingle JN, et al, &ldquo;Combination of Paclitaxel and Carboplatin as Second-Line Therapy for Patients With Metastatic Melanoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(2):375-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16342250/pubmed\" id=\"16342250\" target=\"_blank\">",
"        16342250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robert N, Leyland-Jones B, Asmar L, et al,  &ldquo;Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2786-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16782917/pubmed\" id=\"16782917\" target=\"_blank\">",
"        16782917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Wilson MW, Haik BG, et al, &ldquo;Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(10):2019-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12743157/pubmed\" id=\"12743157\" target=\"_blank\">",
"        12743157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1998, 77(12):2310-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/9649151/pubmed\" id=\"9649151\" target=\"_blank\">",
"        9649151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Plantaz D, Coze C, et al, \"Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,\"",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 2001, 36(1):247-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11464897/pubmed\" id=\"11464897\" target=\"_blank\">",
"        11464897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandler A, Gray R, Perry MC, et al, &ldquo;Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(24):2542-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/17167137/pubmed\" id=\"17167137\" target=\"_blank\">",
"        17167137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schiller JH, Harrington D, Belani CP, et al, &ldquo;Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(2):92-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11784875/pubmed\" id=\"11784875\" target=\"_blank\">",
"        11784875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmittel A, Fischer von Weikersthal L, Sebastian M, et al, &ldquo;A Randomized Phase II Trial of Irinotecan Plus Carboplatin Versus Etoposide Plus Carboplatin Treatment in Patients With Extended Disease Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(4):663-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16423848/pubmed\" id=\"16423848\" target=\"_blank\">",
"        16423848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Secord AA, Havrilesky LJ, Carney ME, et al, &ldquo;Weekly Low-Dose Paclitaxel and Carboplatin in the Treatment of Advanced or Recurrent Cervical and Endometrial Cancer,&rdquo;",
"      <i>",
"       Int J Clin Oncol",
"      </i>",
"      , 2007, 12(1):31-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/17380438/pubmed\" id=\"17380438\" target=\"_blank\">",
"        17380438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shields CL, Honavar SG, Meadows AT, et al, \"Chemoreduction for Unilateral Retinoblastoma,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2002, 120(12):1653-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12470138/pubmed\" id=\"12470138\" target=\"_blank\">",
"        12470138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skarlos DV, Samantas E, Briassoulis E, et al, &ldquo;Randomized Comparison of Early Versus Late Hyperfractionated Thoracic Irradiation Concurrently With Chemotherapy in Limited Disease Small-Cell Lung Cancer: A Randomized Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2001, 12(9):1231-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/11697833/pubmed\" id=\"11697833\" target=\"_blank\">",
"        11697833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauss GM, Herndon JE 2nd, Maddaus AA, et al, &ldquo;Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(31):5043-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18809614/pubmed\" id=\"18809614\" target=\"_blank\">",
"        18809614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sussman DA, Escalona-Benz E, Benz MS, et al, \"Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2003, 121(7):979-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12860801/pubmed\" id=\"12860801\" target=\"_blank\">",
"        12860801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tinker AV, Bhagat K, Swenerton KD, et al, &ldquo;Carboplatin and Paclitaxel for Advanced and Recurrent Cervical Carcinoma: The British Columbia Cancer Agency Experience,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2005, 98(1):54-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15904950 /pubmed\" id=\"15904950 \" target=\"_blank\">",
"        15904950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valero V, Forbes J, Pegram MD, et al, &ldquo;Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab as First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens,",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(2):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/21115860/pubmed\" id=\"21115860\" target=\"_blank\">",
"        21115860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Meerten E, Muller K, Tilanus HW, et al, &ldquo;Neoadjuvant Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Patients With Oesophageal Cancer: A Phase II Study,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2006, 94(10):1389-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/16670722/pubmed\" id=\"16670722\" target=\"_blank\">",
"        16670722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Winkle P, Angiolillo A, Krailo M, et al, &ldquo;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children&rsquo;s Cancer Group (CCG) Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):338-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15503297/pubmed\" id=\"15503297\" target=\"_blank\">",
"        15503297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasey PA, Jayson GC, Gordon A, et al, \"Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma,\"",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(22):1682-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/15547181/pubmed\" id=\"15547181\" target=\"_blank\">",
"        15547181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vaughn DJ, Manola J, Dreicer R, et al, &ldquo;Phase II Study of Paclitaxel Plus Carboplatin in Patients With Advanced Carcinoma of the Urothelium and Renal Dysfunction (E2896): A Trial of the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(5):1022-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/12209686/pubmed\" id=\"12209686\" target=\"_blank\">",
"        12209686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Mesia R, Rivera F, et al, &ldquo;Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(11):1116-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/18784101/pubmed\" id=\"18784101\" target=\"_blank\">",
"        18784101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandt H, Birkmann J, Denzel T, et al, &ldquo;Sequential Cycles of High-Dose Chemotherapy With Dose Escalation of Carboplatin With or Without Paclitaxel Supported by G-CSF Mobilized Peripheral Blood Progenitor Cells: A Phase I/II Study in Advanced Ovarian Cancer,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1999, 23(8):763-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/10231137/pubmed\" id=\"10231137\" target=\"_blank\">",
"        10231137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss GR, Green S, Hannigan EV, et al, &ldquo;A Phase II Trial of Carboplatin for Recurrent or Metastatic Squamous Carcinoma of the Uterine Cervix: A Southwest Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 1990, 39(3):332-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/61/38873/abstract-text/2258080/pubmed\" id=\"2258080\" target=\"_blank\">",
"        2258080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9202 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38873=[""].join("\n");
var outline_f37_61_38873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708661\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146189\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146239\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146192\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146217\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146193\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146194\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146195\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3272713\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146152\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146171\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146245\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146170\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146235\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146248\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146237\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146174\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146156\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298973\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146161\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146185\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146163\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923584\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146204\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3272444\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323041\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146165\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146176\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146155\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146173\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9202\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9202|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/18/40228?source=related_link\">",
"      Carboplatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/10/43174?source=related_link\">",
"      Carboplatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38874="Overview of the risks and benefits of alcohol consumption";
var content_f37_61_38874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the risks and benefits of alcohol consumption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Kenneth J Mukamal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/61/38874/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/61/38874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use represents an unusual paradox for clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/1\">",
"     1",
"    </a>",
"    ]. Humans have used it safely and enjoyably for millennia, and it occupies an important place in many secular and religious ceremonies. In addition, moderate alcohol consumption may actually improve health. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a subset of alcohol drinkers develop catastrophic complications related to its use. Integrating these risks and benefits into a recommendation about drinking alcohol poses a challenge and will be discussed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PITFALLS IN STUDIES OF ALCOHOL CONSUMPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No long-term randomized trials of alcohol administration exist. Our knowledge of the effects of moderate alcohol consumption in humans is derived primarily from two sources: short-term trials analyzing the effect of alcohol upon physiological measures and observational studies comparing moderate drinkers with abstainers. Neither of these sources is without limitation.",
"   </p>",
"   <p>",
"    Short-term trials of alcohol intake must focus upon intermediate measures rather than disease outcome. Examples include measurement of alcohol's effect upon hemostatic parameters, lipid levels, or cognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These studies do little to inform debate about the balance between alcohol's long-term risks and benefits since public alcohol use extends over decades. Furthermore, these trials tend to be performed using healthy, young, white male subjects; the results cannot necessarily be extrapolated to other populations.",
"   </p>",
"   <p>",
"    The main difficulty of observational studies that compare abstainers with alcohol users is that alcohol use is not distributed randomly among individuals; people who abstain are different than those who drink in more ways than just how much alcohol they consume. Simply adjusting for known, measurable differences between abstainers and drinkers may be inadequate to make the two groups comparable. Some of the differences that are difficult to measure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cessation of drinking with illness",
"      </strong>",
"      &mdash; People who are ill (whether they realize it or not) may stop drinking. If they do, the group of healthy abstainers will be diluted with former drinkers at high-risk for illness and death. As an example, the British Regional Heart Study found that a large proportion of abstainers were former drinkers with high rates of high blood pressure, chronic bronchitis, and coronary heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Even patients who have asymptomatic chronic diseases may avoid alcohol to prevent interactions with medications that they take. The remarkably wide range of illness associated with abstention fits this explanation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Inclusion of former alcoholics",
"      </strong>",
"      &mdash; People who remain in remission from alcoholism rarely return to social drinking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, they are more likely to be abstainers than moderate drinkers. People may be particularly loathe to admit that former alcoholism is the reason behind their current abstention since alcoholism carries a strong social stigma.",
"     </li>",
"     <li>",
"      <strong>",
"       Abstention as an indicator of underlying emotional or physical problems",
"      </strong>",
"      &mdash; The decision to avoid alcohol in moderation may itself reflect important facts about one's physical and emotional health. This was illustrated in a prospective study of 400 men from adolescence into older age; 33 percent of lifelong abstainers had poor physical health in childhood compared with 14 percent of moderate drinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, only 16 percent of abstainers came from warm childhood homes versus 35 percent of moderate drinkers.",
"      <br/>",
"      <br/>",
"      Similarly, an analysis of 9605 individuals at age 33 demonstrated that abstainers had double the risk of psychological distress or limiting illness than light or moderate drinkers, regardless of gender [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/9\">",
"       9",
"      </a>",
"      ]. This implies that abstainers differ from drinkers well before differences in specific diseases emerge.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate alcohol use as a marker of socioeconomic status",
"      </strong>",
"      &mdash; Moderate alcohol use is more common among those with higher socioeconomic status, at least in the United States. In one study, for example, current drinkers were 15 to 25 percent more likely to have attended school beyond grade 12 than were lifelong nondrinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"       10",
"      </a>",
"      ]. In a meta-analysis of 10 population studies, lifelong abstainers were of lower socioeconomic status than light drinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/11\">",
"       11",
"      </a>",
"      ]. Because of the profound effect of socioeconomic status on health, its potential for confounding the observed effect of alcohol is considerable.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate alcohol use as an indicator of resistance to alcoholism",
"      </strong>",
"      &mdash; People who successfully drink in moderation are, by definition, not abusers of alcohol; they have undergone a \"diagnostic challenge\" for alcoholism and passed. The same cannot be said for lifelong abstainers. If abstainers were to initiate alcohol consumption, some would develop problem drinking. Thus, one must generalize the results of observational studies comparing moderate drinkers and abstainers with caution. This problem does not apply to studies comparing infrequent with moderate drinkers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND THE \"IDEAL DOSE\" OF ALCOHOL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159190429\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitions of a \"standard drink\" differ, both within and between countries (",
"    <a class=\"graphic graphic_table graphicRef59031 \" href=\"mobipreview.htm?1/3/1073\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. For different countries, a standard drink is generally considered as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      United States (US): 14 to 15 g alcohol (0.5 to 0.6 fl oz), equivalent to 12 oz beer, 5 oz wine, and 1.5 oz of 80 proof liquor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Great Britain: 8 g alcohol",
"     </li>",
"     <li>",
"      Japan: 19.75 g alcohol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Standard drinks are depicted for the US (",
"    <a class=\"graphic graphic_figure graphicRef56818 \" href=\"mobipreview.htm?20/18/20778\">",
"     figure 1",
"    </a>",
"    ). Analogous representations are available for the",
"    <a class=\"external\" href=\"file://www.nhs.uk/Livewell/alcohol/Pages/alcohol-units.aspx\">",
"     United Kingdom",
"    </a>",
"    and for",
"    <a class=\"external\" href=\"file://www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/E9E12B0E00E94FD5CA25718E0081F1DC/$File/std0910.pdf\">",
"     Australia",
"    </a>",
"    (also applicable to France, Hungary, Ireland, New Zealand, Poland, and Spain).",
"   </p>",
"   <p>",
"    In addition to the amount of alcohol in \"one drink,\" cut points to define \"moderate\" and \"heavy\" drinking also vary. In the US, the following parameters generally apply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate drinking: low risk for alcohol problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women: &lt;2 drinks per day",
"     </li>",
"     <li>",
"      Men: &lt;3 drinks per day",
"     </li>",
"     <li>",
"      People age &ge;65: &lt; 2 drinks per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heavy drinking: at risk for alcohol problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women: &gt;7 drinks per week or 3 drinks per occasion",
"     </li>",
"     <li>",
"      Men: &gt;14 drinks per week or 4 drinks per occasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binge drinking:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women: 4 or more drinks in one drinking occasion",
"     </li>",
"     <li>",
"      Men: 5 or more drinks in one drinking occasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159190596\">",
"    <span class=\"h2\">",
"     The \"ideal dose\" of alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;No level of alcohol consumption can reliably be regarded as safe for some people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/16\">",
"     16",
"    </a>",
"    ]. Conditions that generally contraindicate",
"    <strong>",
"     any",
"    </strong>",
"    alcohol use include pregnancy, personal or strong family history of alcoholism, previous hemorrhagic stroke, hepatic or pancreatic disease, and operation of potentially dangerous equipment or machinery. On the other hand, cardiovascular disease remains the most common cause of death in many of these subgroups, suggesting that the absolute mortality benefit from modest alcohol use could equal its risk. In the absence of more data, however, current recommendations remain that these individuals abstain from all alcohol. Alcohol use should be limited in patients with other conditions, including active gastritis, esophagitis, premalignant GI lesions such as Barrett's esophagus, or a strong family history of breast cancer.",
"   </p>",
"   <p>",
"    For people without these conditions, the healthiest dose of alcohol has not been definitively determined. Several studies suggest that men can tolerate more alcohol than women. The ideal dose of alcohol is likely around 6 grams per day. One portion of alcohol, approximately 10 to 15 grams of ethanol, can be found in one glass of wine, one can or bottle of beer, or one mixed drink (",
"    <a class=\"graphic graphic_figure graphicRef56818 \" href=\"mobipreview.htm?20/18/20778\">",
"     figure 1",
"    </a>",
"    ). This is based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of the association between alcohol and nonfatal myocardial infarction found no additional benefit above 0.5 portion daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of data from 29 cohort studies found that the lowest mortality was associated with consumption of 5 to 7 grams of alcohol per day (about one drink every other day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more recent meta-analysis of 34 studies, using the same methodology as the analysis above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/18\">",
"       18",
"      </a>",
"      ] but including 10 subsequently published studies, again found that mortality was lowest at an intake of approximately 6 grams per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/19\">",
"       19",
"      </a>",
"      ]. Although the benefit was equally strong among men and women, the dose associated with lowest mortality was lower in women than men (4",
"      <span class=\"nowrap\">",
"       gm/day",
"      </span>",
"      and 6 to 7",
"      <span class=\"nowrap\">",
"       gm/day",
"      </span>",
"      respectively). Women who drank up to two glasses of alcoholic beverage daily, and men who drank up to four glasses, had lower mortality than people who had never consumed alcohol. Twenty-six of the studies were from populations outside the US and, as noted below, the effects of alcohol vary in different geographical locations.",
"     </li>",
"     <li>",
"      In the largest study of alcohol and mortality, the maximal benefit occurred at a consumption of one drink daily for both men and women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 86,000 nurses found mortality to be lowest among those women consuming one to three drinks per week (RR = 0.83 compared with abstainers), slightly lower than the mortality for women consuming up to two drinks daily (RR = 0.88 compared with abstainers) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/20\">",
"       20",
"      </a>",
"      ]. This apparent survival benefit was largely confined to women at greatest risk for coronary heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Established recommendations for safe levels of drinking differ between men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/16\">",
"     16",
"    </a>",
"    ]. These recommendations do not address an \"ideal\" level of alcohol consumption, but advise no more than two drinks daily for men and one drink daily for women. The reasons for this gender difference include the lower body size, percentage of body weight composed of water, and activity of gastric alcohol dehydrogenase among women, resulting in heavier effective alcohol exposure for a given level of drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to gender, geography also may alter the \"ideal dose\" of alcohol. For reasons that are not entirely clear, the nadir of the U-shaped mortality curve for alcohol consumption shifts according to the drinking habits of the country studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/24\">",
"     24",
"    </a>",
"    ]. This finding corroborates the central role of cultural factors in shaping how alcohol affects health, both at moderate and extreme consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ALCOHOL AND TOTAL MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problem drinking is clearly related to excess mortality (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    ). A case control study in one Russian city found that the mortality odds ratio (adjusted for education and smoking) was 3.0 (95% CI 2.2-4.0) for men aged 25 to 54 who were problem drinkers compared to non-problem drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/26\">",
"     26",
"    </a>",
"    ]. Problem drinking included such indicators as frequent hangover, excessive drunkenness, or sleeping in one's clothes.",
"   </p>",
"   <p>",
"    Moderate drinkers generally have lower mortality rates than abstainers or heavy drinkers. This finding has been observed in prospective studies from around the world, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10,20,27\">",
"     10,20,27",
"    </a>",
"    ], Great Britain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/28\">",
"     28",
"    </a>",
"    ], Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/29\">",
"     29",
"    </a>",
"    ], Trinidad [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/30\">",
"     30",
"    </a>",
"    ], Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/31\">",
"     31",
"    </a>",
"    ], and China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/32\">",
"     32",
"    </a>",
"    ], among many others. Ecological analyses also support this conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of death for moderate drinkers is generally 0.7 to 0.9 compared with abstainers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 490,000 adults, the relative risk of death for those who reported consuming one drink per day was about 0.8 relative to abstainers (",
"      <a class=\"graphic graphic_figure graphicRef82332 \" href=\"mobipreview.htm?26/32/27150\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"       10",
"      </a>",
"      ]. Even heavy drinkers had marginally lower total mortality than abstainers.",
"     </li>",
"     <li>",
"      A study of 277,000 men found relative risks of death of 0.84 and 1.38 for those reporting consumption of one and six or more drinks daily, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report of 12,000 British male doctors found that the relative risk of death from all causes was 0.7 for those consuming 8 to 14 drinks per week relative to abstainers, with a pattern nearly identical to the last study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moderate alcohol intake is associated with lower total mortality even among hypertensive patients whose blood pressure might be increased by alcohol intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality benefit of alcohol may not be distributed evenly within the population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate alcohol use should be most beneficial for those at highest risk for heart disease. Thus, older patients derive more absolute benefit from alcohol than younger individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10,37\">",
"       10,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of 3383 Danish men found that alcohol consumption was only protective for men with Lewis blood group Le(a-b-), who are particularly prone to ischemic heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/38\">",
"       38",
"      </a>",
"      ]. A subsequent analysis of 1735 individuals from the Framingham Offspring Study supported greater benefit for alcohol use in those who carried mutations of the 3(FUT3) gene, also known as the Lewis gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six-year follow-up from the Copenhagen Male Study found that alcohol protected against coronary heart disease only among men with the highest baseline LDL concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study of 396 men with myocardial infarction and 770 control men studied two forms (alleles) of the alcohol dehydrogenase 3 gene, one which metabolizes ethanol quickly (reducing the body's exposure to alcohol) and one which metabolizes it slowly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/41\">",
"       41",
"      </a>",
"      ]. Compared with rare drinkers and abstainers who had two copies of the faster allele, daily drinkers with two copies of the faster allele had a 38 percent lower risk of myocardial infarction, while daily drinkers with two copies of the slower allele had an 86 percent lower risk of myocardial infarction. Thus, men who sustain the longest exposure upon drinking alcohol (because of genetic variation in the breakdown of alcohol) appear to gain the most cardiovascular benefit from drinking. This finding was also supported by evidence on prevalent myocardial infarction from the Framingham Offspring Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/42\">",
"       42",
"      </a>",
"      ]. The alcohol dehydrogenase gene, however, does not appear to have a similar impact on the risk of stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of analyses of a cohort study of 5888 older adults, intake of one to six drinks per week was shown to decrease levels of inflammatory markers (including CRP and fibrinogen) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/44\">",
"       44",
"      </a>",
"      ] and to lower the risk of dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/45\">",
"       45",
"      </a>",
"      ] and ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/46\">",
"       46",
"      </a>",
"      ]. However, this relationship was reversed in subjects who lacked the E4 allele of the apoE gene (which has been linked to increased risk of Alzheimer disease). In such individuals, alcohol intake increased levels of CRP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/44\">",
"       44",
"      </a>",
"      ]. Light intake did not lower risk of dementia or stroke, and alcohol intake of seven drinks or more per week substantially increased ischemic stroke risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Beverage types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The French paradox, that coronary heart disease mortality is lower in France than would be expected from the high national prevalence of smoking and saturated fat intake, has been attributed to frequent red wine consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/47\">",
"     47",
"    </a>",
"    ]. Red wine contains phenolic and flavonoid substances that have antithrombotic and antioxidant properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/48\">",
"     48",
"    </a>",
"    ], and have been found to reduce atherosclerosis in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/49\">",
"     49",
"    </a>",
"    ]. De-alcoholized red wine, but not de-alcoholized white wine, has demonstrated potentially cardioprotective effects on platelets and vascular physiology in small human studies, but whether these will directly affect risk for myocardial infarction is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a systematic review found that all beverage types are associated with lower rates of coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar findings were noted in other reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prospective studies from China and Germany, where beer is the predominant alcoholic beverage, confirm the J-shaped relationship between alcohol use and total mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/32,52\">",
"       32,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case control study of 561 men with myocardial infarction and 643 healthy controls recruited from France and Northern Ireland found that alcohol consumption was associated with a comparably decreased rate of myocardial infarction in both countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/53\">",
"       53",
"      </a>",
"      ]. This effect was due to wine consumption in France and non-wine consumption in Northern Ireland.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether beverage type matters for specific diseases other than coronary heart disease is still uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Resveratrol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resveratrol (3,5,4'-trihydroxystilbene) is a substance produced by plants in response to stress, and is found in grape skin and red wine. Resveratrol extends the life of non-mammalian organisms, and was demonstrated to improve the metabolic profile and lifespan of mice fed high fat diets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/54\">",
"     54",
"    </a>",
"    ]. Mice provided with resveratrol 22.4 mg per kg daily and fed high fat diets, despite lack of weight loss, had survival curves similar to mice fed a standard diet. Additionally, resveratrol enhanced performance of mice on motor skills testing.",
"   </p>",
"   <p>",
"    The resveratrol concentration of red wine is 1.5 to 3 mg per liter; a 70 kg person would need to consume over 1000 liters of red wine daily to achieve the resveratrol concentrations in this study. Resveratrol supplements are currently marketed, but tablet doses are not standardized and side effects are unknown; these supplements are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H739563958\">",
"    <span class=\"h1\">",
"     ALCOHOL AND OVERALL HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problem drinking reduces the quality of life for patients and their families (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    ). However, few studies have evaluated how moderate alcohol use affects quality of life. Two European cross-sectional studies found that self-reported health was best among subjects who consumed one to two drinks daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Use of sick leave also shows this J-shaped relationship with alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/57\">",
"     57",
"    </a>",
"    ]. As noted above, abstainers may be prone to poor subjective health even in their youth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 4276 noninstitutionalized adults aged 50 years and older found that moderate drinking (&lt;15 drinks per week AND &lt;5 drinks per day for men or &lt;4 per day for women) was associated with 25 percent lower risk for disability, compared with abstention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/58\">",
"     58",
"    </a>",
"    ]. This benefit was restricted to adults who reported themselves to be in good or better health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALCOHOL AND SPECIFIC ILLNESSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of alcohol consumption on cardiac disease, hypertension, peripheral vascular disease, and stroke are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    ). The association of alcohol use and atrial fibrillation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Alcohol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H30#H30\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Caffeine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4656216\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use has been associated with increased risk for multiple cancers. A meta-analysis of 18 cohort studies found a J-shaped relationship between all cancer mortality and alcohol intake in men, although not in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/59\">",
"     59",
"    </a>",
"    ]. The pooled relative risks for cancer mortality for light, moderate, and heavy drinkers in this meta-analysis were 0.91 (95% CI 0.89-0.94), 1.02 (CI 0.99-1.06), and 1.31 (CI 1.23-1.39), respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is consistent evidence that breast cancer risk is higher for women consuming low (less than one",
"    <span class=\"nowrap\">",
"     drink/day)",
"    </span>",
"    to high (three or more",
"    <span class=\"nowrap\">",
"     drinks/day)",
"    </span>",
"    levels of alcohol compared with abstainers, and there appears to be a significant dose response relationship beginning with intakes as low as three to six drinks per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. A 2013 meta-analysis of 110 epidemiologic studies showed a small but significant association between female breast cancer and light alcohol intake (RR 1.05, 95% CI 1.02-1.08) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of several cohort studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest cohort study examining the relationship between alcohol and breast cancer, 105,986 women in the Nurses&rsquo; Health Study were followed from 1980 until 2008 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/62\">",
"       62",
"      </a>",
"      ]. The power of this study enabled detection of a small increased risk of breast cancer (RR 1.15, 95% CI 1.06-1.24) at levels of alcohol consumption equivalent to three to six drinks per week, compared to abstainers. There was a 10 percent increase in risk with each 10 g per day of alcohol intake. Breast cancer risk was linearly correlated with cumulative lifetime alcohol intake and was most strongly associated with drinking patterns in both early and later adult life.",
"     </li>",
"     <li>",
"      In a pooled analysis of 322,000 women, the risk of breast cancer rose linearly with increasing alcohol consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/64\">",
"       64",
"      </a>",
"      ]. Every 10 gram increase in daily alcohol intake (about 70 percent of a standard drink) was associated with a 9 percent increase in breast cancer risk relative to abstainers. The risk of breast cancer was increased by 41 percent for women consuming two to five drinks per day. This increase in risk was present for all beverage types and in all subgroups studied.",
"     </li>",
"     <li>",
"      In an analysis of breast cancer incidence among 38,500 women participating in the Women's Health Study, daily alcohol intake again was shown to modestly increase risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/65\">",
"       65",
"      </a>",
"      ]. The relative risk for each 10 gram increase in daily alcohol intake was 1.11 (95% CI 1.03-1.20) for ER and PR positive breast cancer; the difference in risk was not statistically significant for ER and PR negative breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proportion of breast cancer cases attributed to alcohol intake varies widely; in the United States the population attributable risk is estimated to be only 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/66\">",
"     66",
"    </a>",
"    ]. In Italy, however, where alcohol intake is higher, alcohol has been estimated to account for 11 percent of breast cancer cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/67\">",
"     67",
"    </a>",
"    ]. In the EPIC (European Prospective Investigation into Cancer and Nutrition) study in over 250,000 women in eight European countries, the attributable risk for breast cancer was 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/68\">",
"     68",
"    </a>",
"    ]. In large part, the increased risk occurred in individuals who drank alcohol in excess of the recommended upper limit.",
"   </p>",
"   <p>",
"    An additive risk for the combination of postmenopausal hormone therapy and alcohol intake was reported in the Nurses' Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/69\">",
"     69",
"    </a>",
"    ]. Compared with women who neither took hormones nor drank alcohol, the risk of breast cancer was significantly increased approximately 1.3-fold in women who either drank alcohol or took postmenopausal hormone supplements, but was two-fold higher in those who drank more than one alcoholic drink per day and used hormones for five or more years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of biological mechanisms may explain the association between breast cancer and alcohol intake, including increased circulating estrogens and androgens, enhancement of mammary gland susceptibility to carcinogenesis, increased mammary carcinogen DNA damage, and greater potential for invasiveness of breast cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hormonal basis for the effect of alcohol on breast cancer is possible, consistent with its effects on estrogen levels and osteoporosis. A population-based study of women aged 65 to 79 from Washington state found that alcohol increased the risk of estrogen and progesterone receptor positive",
"    <span class=\"nowrap\">",
"     (ER+/PR+)",
"    </span>",
"    breast tumors more than the risk of",
"    <span class=\"nowrap\">",
"     ER-/PR-",
"    </span>",
"    tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/70\">",
"     70",
"    </a>",
"    ]. Another cohort study of 51,847 postmenopausal Swedish women demonstrated an association between increased alcohol intake and ER+ breast cancer, regardless of PR status (RR 1.35, 95% CI 1.02-1.80) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    intake may attenuate the effect of alcohol consumption on breast cancer. In the Nurses' Health Study, consumption of one or more drinks per day was associated with a nonsignificant 5 percent increase in risk of breast cancer among women who consumed at least 300 micrograms of folic acid daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/72\">",
"     72",
"    </a>",
"    ]. In contrast, alcohol use was associated with a 32 percent increased risk of breast cancer in women with lower folate intake. A follow-up nested case-control study looked at plasma levels of folate and found that among women who consumed one or more drinks per day, the relative risk (RR) for breast cancer was 0.11 (95% CI 0.02-0.59) among women in the highest compared with lowest quintiles of plasma folate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the Iowa Women's Health Study found that folate intake can modify the higher risk of breast cancer in women who drink alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/74\">",
"     74",
"    </a>",
"    ]. In contrast to some of the studies described above, in this study the higher risk of breast cancer among regular drinkers (and thus the protective effect of folate) was limited to estrogen receptor negative tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/75\">",
"     75",
"    </a>",
"    ]. The reason for this disparate result is not clear.",
"   </p>",
"   <p>",
"    At a minimum, these reports suggest that women who consume alcohol should also take a daily multivitamin fortified with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/76\">",
"     76",
"    </a>",
"    ]. It is uncertain if supplemental folate intake is necessary in the United States (US) where grain is fortified with folic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gastrointestinal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of gastrointestinal cancer are linked to alcohol consumption, even at low levels of intake. In a study of 226,000 men, the combined mortality rate for cancers of the mouth, larynx, pharynx, esophagus, and liver was 40 percent higher in less-than-daily drinkers than in abstainers and rose progressively with heavier consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"     10",
"    </a>",
"    ]. In the large European EPIC study, the alcohol-related attributable risk for men and women, respectively, was 44 and 25 percent for upper gastrointestinal cancer, 33 and 18 percent for hepatocellular cancer, and 17 and 4 percent for colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/68\">",
"     68",
"    </a>",
"    ]. As with breast cancer, the increased risk in large part was found in individuals who drank more than the recommended upper limit.",
"   </p>",
"   <p>",
"    Most evidence suggests that beverage type does not substantially alter risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Oral cavity, larynx, and pharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cancers of the oral cavity, larynx, and pharynx rise linearly with alcohol consumption; no clear safe threshold of consumption has been reliably identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/78\">",
"     78",
"    </a>",
"    ]. A 2013 meta-analysis of 36 epidemiologic studies demonstrated that light alcohol intake (&lt;1 drink per day) was associated with an increase in risk of oropharyngeal cancer (RR 1.17, 95% CI 1.06-1.29) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/63\">",
"     63",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    A prospective study of over one million women (average age 56 years) found that, at an average follow-up of 7.5 years, intakes between 3 and 14 drinks per week were associated with a slightly increased risk of cancer of the oral cavity and pharynx (RR 1.13); risk was two-fold higher for those who drank 15 or more drinks per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/61\">",
"     61",
"    </a>",
"    ]. The relative risk for a 10 g (approximately one drink) per day increment in alcohol was 1.07 for wine and 1.38 for other alcoholic beverages, consistent with a higher risk for beverages with more concentrated alcohol content.",
"   </p>",
"   <p>",
"    For people with a history of problem drinking, the risk of head and neck cancer is increased up to ten years of quitting drinking, but after twenty years of alcohol cessation there is no longer increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although alcohol exposure in mouthwash has been reported to increase the risk of oral cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/80\">",
"     80",
"    </a>",
"    ], a systematic review concluded that such a link is unlikely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who smoke and drink are at greater risk than would be expected from either factor alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Esophageal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of squamous cell esophageal cancer also is strongly related to alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. However, alcohol does not appear to be associated with increased risk for esophageal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether there is a safe level of drinking with regard to esophageal cancer risk is unclear. A 2013 meta-analysis (27 studies) demonstrated that even light (less than one drink per day) alcohol drinking was associated with an increase in esophageal squamous cell cancer (RR 1.30, 95% CI 1.09-1.56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk for squamous cell esophageal cancer in people with problem drinking decreases rapidly after two years of alcohol cessation and, as with head and neck cancers, is no higher than among never drinkers after 20 years of alcohol cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Colorectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of colorectal cancer may be related to alcohol use, but the association appears to be weak and study results have varied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10,61,86-90\">",
"     10,61,86-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a 1990 meta-analysis of 27 studies found that people who consumed two drinks daily had a 10 percent increased risk of colorectal cancer compared with abstainers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/86\">",
"     86",
"    </a>",
"    ]. In contrast, alcoholics do not appear to be at increased risk for developing colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A study of 42,000 postmenopausal women found that moderate drinkers had lower rates of distal colon cancer than abstainers (relative risk = 0.6 to 0.7), while no effect of alcohol intake was seen for proximal colon cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of over one million women (average age 56 years) found no association of alcohol intake with colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/61\">",
"     61",
"    </a>",
"    ]. The risk for rectal cancer was not significantly increased for women who consumed between 3 and 14 drinks per week, but was 25 percent higher for those consuming 15 or more drinks per week.",
"   </p>",
"   <p>",
"    Consistent with this, an effect of gender on risk was seen in a study of 490,000 adults in the United States; the death rate from colon cancer rose slightly with increasing alcohol consumption in men, but dropped significantly among women who consumed one drink daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a study of 29,000 people in Japan found a positive dose-response relationship between alcohol consumption and colon cancer risk in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/88\">",
"     88",
"    </a>",
"    ]. Similarly, a study that pooled data from eight large prospective studies from North America and Europe looked at the relationship between a single baseline determination of alcohol intake and the incidence of colorectal cancer in 489,979 people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/91\">",
"     91",
"    </a>",
"    ]. Compared with nondrinkers, those who consumed 30 to less than 45 g per day of alcohol had a relative risk (RR) of colorectal cancer of 1.16 (95% CI 0.99-1.36) and those who consumed more than 45 g per day had a RR of 1.41 (CI 1.16-1.72); the relative risks in men and women appeared similar, and the association was seen for cancers of all portions of the colon and rectum.",
"   </p>",
"   <p>",
"    The reason for these disparate findings is unclear. In addition to the possible effect of gender, the relationship between alcohol and colorectal cancer may be modified by type of alcoholic beverage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/92\">",
"     92",
"    </a>",
"    ]. In the large pooled study described above, however, no clear differences in relative risk were found for different beverage types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/91\">",
"     91",
"    </a>",
"    ]. Dietary intake of folate may also modify the relationship between alcohol and colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Low dietary folate may increase the effect of alcohol intake on the risk of colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Folic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Pancreatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancer is not clearly related to alcohol intake. One study of 34,000 women found a trend toward increased risk of pancreatic cancer with heavier alcohol consumption (p = 0.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/95\">",
"     95",
"    </a>",
"    ], but many other reports have found no such relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. Two case-control studies found that only heavy drinking (over five drinks daily) was associated with pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Hepatocellular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma has been linked to alcohol use. Much of this association may be mediated by alcoholic cirrhosis, since cirrhosis of any cause is a major cause of this malignancy. Alcohol, possibly even at low levels of consumption, also exacerbates the increased risk of hepatocellular carcinoma incurred by carriers of hepatitis B or hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=see_link\">",
"     \"Hepatitis C and alcohol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several case-control studies that have found little risk of hepatocellular carcinoma among mild drinkers when they are separated from heavy drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. A large prospective study of middle-aged women found no increased risk for liver cancer among consumers of 3 to 6 drinks per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/61\">",
"     61",
"    </a>",
"    ]. Although there was a 20 percent higher risk among women drinking 7 to 14 drinks per week, this was not statistically significant. However, risk was significantly increased by 70 percent among women consuming more than 14 drinks weekly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are unclear whether alcohol intake promotes lung cancer. Since there is a strong association between smoking and drinking throughout the world, studies may be confounded if not adequately controlled for tobacco use. One study of 4265 participants in the original Framingham Study cohort and 4793 participants in the Framingham offspring cohort compared risks for lung cancer with levels of drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/107\">",
"     107",
"    </a>",
"    ]. Alcohol intake in these cohorts was mostly light to moderate. No relationship between alcohol and lung cancer was found, after adjustment for cigarette use. A meta-analysis also found no evidence of increased cancer risk except for individuals with very high alcohol intakes (&gt;2000",
"    <span class=\"nowrap\">",
"     gm/month",
"    </span>",
"    or five to six drinks per day), in whom there was still the strong possibility of confounding by cigarette smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonmalignant liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, low levels of alcohol consumption do not clearly cause cirrhosis. It is generally believed that heavy alcohol intake (at least five drinks daily) is needed to cause cirrhosis in men (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    ); many epidemiological studies have found that liver disease is unusual among moderate drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In contrast, a study of 277,000 men noted elevated risks of death from cirrhosis among mild drinkers relative to abstainers; the relative risks of those who had consumed one or two drinks per day were 1.21 and 3.15, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study of 490,000 adults reported similar results, with relative rates of death from cirrhosis and alcoholism of 1.2 to 1.5 for those who consumed one drink daily, and 2.1 to 2.6 for those who consumed two to three drinks daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the risk associated with moderate drinking may arise from its interaction with other hepatotoxic agents, particularly hepatitis viruses. Even modest drinking may exacerbate the pathogenicity of hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/109\">",
"     109",
"    </a>",
"    ]. A study of 2235 patients with hepatitis C, for example, estimated that consumption of three or fewer drinks daily reduced the expected time to cirrhosis by four years relative to abstainers; consumption greater than this reduced it by an additional four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/110\">",
"     110",
"    </a>",
"    ]. Another study reported a dose-response relationship between alcohol consumption and hepatic inflammation and fibrosis among hepatitis C patients who were very light drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/111\">",
"     111",
"    </a>",
"    ]. Interferon is also less effective in drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/112\">",
"     112",
"    </a>",
"    ]. Current recommendations advise patients with hepatitis C to abstain from alcohol, particularly before initiating therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=see_link\">",
"     \"Hepatitis C and alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cholelithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to liver disease, moderate alcohol intake lowers the risk of gallstones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. In the Nurses' Health Study, women who consumed at least two to three drinks weekly were 40 percent less likely to develop symptomatic gallstones than abstainers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/113\">",
"     113",
"    </a>",
"    ]. Other studies have extended this observation to men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/115-118\">",
"     115-118",
"    </a>",
"    ]. The mechanism of this protective benefit may be an alcohol-induced reduction in the biliary cholesterol saturation index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol consumption that is heavy enough to cause liver disease may reverse this benefit. This is suggested by studies that have found a high prevalence of gallstones in patients with alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy alcohol use predisposes to both acute and chronic pancreatitis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    ). Mild alcohol consumption seems to carry an increased relative risk of chronic pancreatitis relative to abstainers, especially in patients with underlying hypertriglyceridemia, although the absolute risk appears to be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/121,122\">",
"     121,122",
"    </a>",
"    ] and not all studies have found elevated risk in moderate drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/123\">",
"     123",
"    </a>",
"    ]. Whether mild alcohol consumption exacerbates the risk of pancreatitis in patients with other risk factors for chronic pancreatitis, such as cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations, is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate alcohol consumption does not appear to be substantially associated with higher or lower risk of renal dysfunction. In the Physicians' Health Study involving 11,023 initially healthy men, there was a trend toward decreased risk of renal dysfunction with greater consumption of alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/124\">",
"     124",
"    </a>",
"    ]. Other studies have not found such an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy alcohol use predisposes to hip fracture by causing both osteoporosis and falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/127,128\">",
"     127,128",
"    </a>",
"    ], although the data on moderate use are mixed. Moderate alcohol use is associated with increased bone mineral density in many studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/129-133\">",
"     129-133",
"    </a>",
"    ], perhaps related to higher endogenous estrogen levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/134\">",
"     134",
"    </a>",
"    ]. On the other hand, studies of actual fractures variously show more fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/135-137\">",
"     135-137",
"    </a>",
"    ], fewer fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/138-140\">",
"     138-140",
"    </a>",
"    ], or no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/141\">",
"     141",
"    </a>",
"    ]. A meta-analysis of observational studies confirmed an apparently nonlinear association of alcohol consumption with osteoporotic fracture but a linear association with bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/142\">",
"     142",
"    </a>",
"    ]. The disparity in the relationships of bone mineral density and fracture risk with alcohol use could relate to an increased risk of trauma or falls that offsets the benefit related to osteoporosis itself. However, a study of alcohol intake and falls among older adults found an increased fall risk only among those who consumed 14 or more drinks per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of diabetes mellitus is decreased in people with moderate alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. In prospective studies of 42,000 men and 85,000 women, for example, the relative risk of diabetes among moderate drinkers (two to three drinks daily for men, one or more drinks daily for women) relative to abstainers was 0.6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/146,147\">",
"     146,147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 15 cohort studies also found a decreased risk for diabetes among light to moderate, but not heavy, alcohol users. Compared with abstainers, the relative risk of diabetes for those who consumed 6 to 12, 12 to 24, 24 to 48, and &ge;48 grams of alcohol daily were 0.70 (95% CI 0.61-0.79), 0.69 (95% CI 0.58-0.81), 0.72 (95% CI 0.62-0.84), and 1.04 (95% CI 0.84-1.29) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cross-sectional studies suggest that moderate drinkers have improved insulin sensitivity and lower plasma insulin levels compared with nondrinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/148-151\">",
"     148-151",
"    </a>",
"    ]. In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/148,152\">",
"     148,152",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/144,146,151,153\">",
"     144,146,151,153",
"    </a>",
"    ] studies, heavier drinking (three or more drinks per day) lowers the risk even more than moderate drinking. However, it is not clear whether these effects are independent of an effect of alcohol upon body-mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized crossover trial in 51 postmenopausal women found that compared with no alcohol consumption, 30 g of alcohol daily (two drinks) for eight weeks lowered serum insulin levels, while leaving glucose levels unchanged, and thus improved insulin sensitivity; 15 g of alcohol daily (one drink) for eight weeks showed a nonsignificant trend toward improving insulin sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/154\">",
"     154",
"    </a>",
"    ]. Triglyceride levels also decreased during exposure to alcohol. This study provides a plausible mechanism for the lower risk of diabetes associated with moderate drinking.",
"   </p>",
"   <p>",
"    Two randomized trials in diabetic individuals confirmed the antihyperglycemic effects of moderate drinking. One study in Israel found that one glass of wine daily (red or white) reduced fasting blood sugar by almost 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/155\">",
"     155",
"    </a>",
"    ]. A similar trial among 115 post-myocardial infarction diabetic patients found that drinking one glass of red wine daily for one year was associated with lower fasting insulin (suggesting better insulin sensitivity), lower levels of oxidative stress and inflammatory markers, and a better ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/156\">",
"     156",
"    </a>",
"    ]. One potential mechanism for these effects is the impact of alcohol on postprandial hyperglycemia. In a feeding study among healthy young adults, alcohol given prior to or with a meal reduced the degree of subsequent glycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential link between moderate drinking and diabetes is the effect of alcohol on adiponectin, an adipocyte hormone which directly improves insulin sensitivity in animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/158\">",
"     158",
"    </a>",
"    ]. Both clinical trials and population studies show that moderate drinking is associated with higher adiponectin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/159,160\">",
"     159,160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mild to moderate alcohol consumption also may decrease the risk of death due to coronary heart disease in older diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/144\">",
"     144",
"    </a>",
"    ]. In one study of 983 diabetics with a mean age of 69 years, the relative risk of coronary heart disease mortality compared with never drinkers was 0.54 for those who drank less than 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (less than one drink per week), and 0.21 for those who drank 14 or more",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (about one drink or more per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, alcohol may worsen diabetic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/162\">",
"     162",
"    </a>",
"    ], and, anecdotally, may induce severe hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/163\">",
"     163",
"    </a>",
"    ]. In a small study (n = 16) of type 1 diabetics, a modest amount of alcohol with the evening meal increased the risk for delayed hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A spectrum of birth defects related to alcohol may occur. Heavy alcohol use can cause the fetal alcohol syndrome, a constellation of findings that include growth retardation, central nervous system dysfunction, and a characteristic facies (",
"    <a class=\"graphic graphic_table graphicRef76082 \" href=\"mobipreview.htm?28/41/29339\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/165\">",
"     165",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate alcohol consumption may produce more subtle growth retardation and neurobehavioral deficits, although this is an area of controversy. A prospective study of 359 newborns found a trend toward increased cranial abnormalities even at low levels of maternal alcohol consumption, suggesting that no safe level of intake exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/166\">",
"     166",
"    </a>",
"    ]. A large case-control study (n&gt;4,700) of babies with congenital abnormalities found that even sporadic intake of only one to two drinks during pregnancy was associated with higher risks of eye abnormalities, and microphthalmia in particular (OR 2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low birth weight may also be a consequence of mild alcohol consumption during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/168\">",
"     168",
"    </a>",
"    ]. In contrast, a 1998 meta-analysis of 130,000 pregnancies concluded that moderate alcohol consumption during the first trimester of pregnancy does not increase the risk of fetal malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/169\">",
"     169",
"    </a>",
"    ]. One author has suggested that the risks of \"misguided alarmism\" about moderate alcohol consumption during pregnancy are even greater than the risks of such drinking itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate alcohol use may raise the risk of spontaneous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/171\">",
"     171",
"    </a>",
"    ]. In a prospective study of 32,000 pregnant women, the relative risks for second-trimester spontaneous abortion were 1.03, 1.98, and 3.53 for less than one drink, one to two drinks (p&lt;0.01), and three or more drinks daily (p&lt;0.01), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/172\">",
"     172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This study found no increased risk in the first trimester, but other prospective studies have found that moderate drinkers suffer more first-trimester abortions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/173\">",
"     173",
"    </a>",
"    ]. On the other hand, another author notes that the association of moderate alcohol use with spontaneous abortion is generally not seen in studies conducted outside North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/174\">",
"     174",
"    </a>",
"    ]; the reason for this disparity is unclear.",
"   </p>",
"   <p>",
"    Despite these controversies, no evidence supports a benefit of alcohol use during pregnancy to the mother or fetus. Thus, consensus recommendations advise complete abstinence from alcohol during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Accidents and trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol is implicated in the morbidity and mortality from trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/176\">",
"     176",
"    </a>",
"    ]. Since most of the trauma risk associated with alcohol is acute, exposure to alcohol is generally measured in blood alcohol concentration (BAC) rather than drinks per day or week. In most of the United States, the legal BAC limit for driving is 0.08 percent. This corresponds to approximately four drinks for a 200 pound man, but only 2.5 drinks for a 150 pound woman.",
"   </p>",
"   <p>",
"    However, the risk of involvement in a collision while driving doubles at a BAC of only 0.05 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/177\">",
"     177",
"    </a>",
"    ]. Furthermore, simulated driving ability is impaired with BACs as low as 0.02 percent (",
"    <a class=\"graphic graphic_figure graphicRef54171 \" href=\"mobipreview.htm?20/63/21490\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/178\">",
"     178",
"    </a>",
"    ]. Alcohol intake is also associated with a greater severity of injury in motor vehicle accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/179\">",
"     179",
"    </a>",
"    ]. The risk of driving accidents is greatest in the first two years of exposure to alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of injuries other than in motor vehicle accidents are also increased by alcohol consumption.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States Federal Aviation Administration has established a BAC offense level of 0.04 percent for pilots in response to data demonstrating impairment in simulated flying ability at this level and above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/181\">",
"       181",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injuries during operation of boats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/182\">",
"       182",
"      </a>",
"      ], bicycles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/183,184\">",
"       183,184",
"      </a>",
"      ], and snowmobiles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/185\">",
"       185",
"      </a>",
"      ] are related to alcohol use.",
"     </li>",
"     <li>",
"      Falls, drowning, burns, hypothermia, and occupational injuries are more prevalent in drinkers, particularly heavy drinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/186\">",
"       186",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol is involved in one-half to two-thirds of all homicides, at least one-half of serious assaults, and more than one-quarter of all rapes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/187\">",
"       187",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18696?source=see_link\">",
"       \"Community violence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether consuming one or two drinks leads to an increased risk of injury is unclear, but several lines of evidence suggest that it does. As noted above, BACs of 0.02 to 0.05 percent impair the ability to operate motor vehicles; this level of blood alcohol can occur with even a single drink. An analysis of 1150 respondents from the 1990 National Alcohol Survey suggests that the risk of injury increases with even one drink daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/188\">",
"     188",
"    </a>",
"    ]. In summary, no safe level of alcohol use exists for the use of potentially dangerous equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use increases the risk of violence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse is associated with an increased risk of suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/189\">",
"     189",
"    </a>",
"    ]. However, moderate drinking does not appear to increase suicide risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/190\">",
"     190",
"    </a>",
"    ]. As an example, in a prospective study of over 128,000 enrollees in a Californian managed care plan, intake of six or more drinks per day was associated with a six-fold higher risk of suicide, but more moderate drinking was not linked to risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/191\">",
"     191",
"    </a>",
"    ]. In a prospective study of 49,000 young Swedish men, death from suicide or probable suicide was linearly related to the level of alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/192\">",
"     192",
"    </a>",
"    ]. A prospective study of 47,000 middle-aged and older men found that risk increased with the quantity of alcohol consumed per occasion and not the frequency of intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/193\">",
"     193",
"    </a>",
"    ]. Even in alcoholics, suicide in most cases is thought to require superimposed episodes of depression rather than alcoholism alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute alcohol use is often a factor in suicide attempts. In a case-crossover study of 102 patients seen in seven emergency departments for suicide attempt, the relative risk for suicide attempt in the six hours following acute ingestion, compared with each patient's usual alcohol consumption, was 9.6 (95% CI 5.7-16.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on alcohol use and risk of dementia are mixed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of older case-control studies and two small cohort studies reported no association between alcohol use and the risk of dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/196-198\">",
"       196-198",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several more recent studies have demonstrated either a lower risk of dementia or a lesser decline in cognitive function over time with mild to moderate alcohol consumption, compared to abstention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/45,199-203\">",
"       45,199-203",
"      </a>",
"      ]. One study found this relationship for older women, but not older men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/204\">",
"       204",
"      </a>",
"      ]. Another study found that the relationship was not sustained when the analysis controlled for premorbid intelligence and physical health [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/205\">",
"       205",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In at least two studies, wine was associated with a decreased risk of dementia, while other beverages were associated with unchanged or slightly increased risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/206,207\">",
"       206,207",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carriers of the apoE genotype were shown to be at increased risk for dementia with increased alcohol consumption in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/208\">",
"       208",
"      </a>",
"      ] but not in another [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/202\">",
"       202",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given this inconsistency in existing data, as well as limitations inherent in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/209\">",
"     209",
"    </a>",
"    ], definitive assessment of the relationship between alcohol use and dementia is not yet possible, but evidence increasingly suggests that light to moderate drinking may be protective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=see_link\">",
"       \"Patient information: Risks and benefits of alcohol (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no simple answer to the question of the health consequences, positive or negative, of alcohol use, but several conclusions can be drawn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals who have been lifelong abstainers cannot be easily compared with moderate or even rare drinkers. Recommending alcohol intake to the abstainers, even if they would agree to drink (which many would not), is fraught with the peril of escalation to problem drinking.",
"     </li>",
"     <li>",
"      The diseases that moderate alcohol use prevents (such as coronary heart disease, ischemic stroke, and diabetes) are most prevalent in older adults, men, and people with coronary heart disease risk factors. For these groups, moderate alcohol use is associated with a substantial mortality benefit relative to abstention or rare drinking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For young to middle aged adults, especially women, moderate alcohol use increases the risk of the most common causes of death (such as trauma and breast cancer). Women who drink alcohol should take supplemental folate to help decrease the risk of breast cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men under the age of 45 also may experience more harm than benefit from alcohol consumption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/61/38874/abstract/210\">",
"       210",
"      </a>",
"      ]. In these younger age groups, moderate alcohol use is unlikely to provide any mortality benefit, but consumption of less than one drink daily appears to be safe if temporally removed from operation of dangerous equipment. For individuals with established contraindications to alcohol use, even that level of alcohol use is dangerous.",
"     </li>",
"     <li>",
"      There have been no long-term randomized trials of alcohol consumption on clinical outcomes. While there is strong evidence of causality based upon epidemiologic studies and short-term trials have found beneficial effects on cardiovascular risk factors, it remains possible that some of the health benefits and risks of alcohol consumption represent associations unrelated to the intake of alcohol itself.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/1\">",
"      Pearson TA, Terry P. What to advise patients about drinking alcohol. The clinician's conundrum. JAMA 1994; 272:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/2\">",
"      Pikaar NA, Wedel M, van der Beek EJ, et al. Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids. Metabolism 1987; 36:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/3\">",
"      Dimmitt SB, Rakic V, Puddey IB, et al. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial. Blood Coagul Fibrinolysis 1998; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/4\">",
"      Maylor EA, Rabbitt PM. Alcohol, reaction time and memory: a meta-analysis. Br J Psychol 1993; 84 ( Pt 3):301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/5\">",
"      Wannamethee G, Shaper AG. Men who do not drink: a report from the British Regional Heart Study. Int J Epidemiol 1988; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/6\">",
"      La Vecchia C, Decarli A, Franceschi S, et al. Prevalence of chronic diseases in alcohol abstainers. Epidemiology 1995; 6:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/7\">",
"      Vaillant GE. A long-term follow-up of male alcohol abuse. Arch Gen Psychiatry 1996; 53:243.",
"     </a>",
"    </li>",
"    <li>",
"     Vaillant GE. Natural History of Alcoholism Revisited, Harvard University Press, Cambridge 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/9\">",
"      Power C, Rodgers B, Hope S. U-shaped relation for alcohol consumption and health in early adulthood and implications for mortality. Lancet 1998; 352:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/10\">",
"      Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997; 337:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/11\">",
"      Fillmore KM, Golding JM, Graves KL, et al. Alcohol consumption and mortality. I. Characteristics of drinking groups. Addiction 1998; 93:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/12\">",
"      Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation 2007; 116:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/13\">",
"      Kerr WC, Greenfield TK, Tujague J, Brown SE. A drink is a drink? Variation in the amount of alcohol contained in beer, wine and spirits drinks in a US methodological sample. Alcohol Clin Exp Res 2005; 29:2015.",
"     </a>",
"    </li>",
"    <li>",
"     file://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm (Accessed on October 10, 2011).",
"    </li>",
"    <li>",
"     National Institute on Alcohol Abuse and Alcoholism. The physicians' guide to helping patients with alcohol problems. Government Printing Office; Washington, DC 1995.",
"    </li>",
"    <li>",
"     United States Department of Agriculture. Dietary guidelines for Americans 2005. Available at: www.health.gov/DIETARYGUIDELINES/dga2005/document/html/chapter9.htm (Accessed on December 12, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/17\">",
"      Maclure M. Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. Epidemiol Rev 1993; 15:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/18\">",
"      Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality. Am J Epidemiol 2004; 159:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/19\">",
"      Di Castelnuovo A, Costanzo S, Bagnardi V, et al. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 2006; 166:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/20\">",
"      Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med 1995; 332:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/21\">",
"      Jones BM, Jones MK. Alcohol effects in women during the menstrual cycle. Ann N Y Acad Sci 1976; 273:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/22\">",
"      Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/23\">",
"      Goist KC Jr, Sutker PB. Acute alcohol intoxication and body composition in women and men. Pharmacol Biochem Behav 1985; 22:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/24\">",
"      Rehm J, Bondy S. Alcohol and all-cause mortality: an overview. Novartis Found Symp 1998; 216:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/25\">",
"      Walsh DC, Cook PJ, Davis K, et al. The cultural dimensions of alcohol policy worldwide. Health Aff (Millwood) 1989; 8:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/26\">",
"      Leon DA, Saburova L, Tomkins S, et al. Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. Lancet 2007; 369:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/27\">",
"      Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. Epidemiology 1990; 1:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/28\">",
"      Duffy JC. Alcohol consumption and all-cause mortality. Int J Epidemiol 1995; 24:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/29\">",
"      Farchi G, Fidanza F, Mariotti S, Menotti A. Alcohol and mortality in the Italian rural cohorts of the Seven Countries Study. Int J Epidemiol 1992; 21:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/30\">",
"      Miller GJ, Beckles GL, Maude GH, Carson DC. Alcohol consumption: protection against coronary heart disease and risks to health. Int J Epidemiol 1990; 19:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/31\">",
"      Kono S, Ikeda M, Tokudome S, et al. Alcohol and mortality: a cohort study of male Japanese physicians. Int J Epidemiol 1986; 15:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/32\">",
"      Yuan JM, Ross RK, Gao YT, et al. Follow up study of moderate alcohol intake and mortality among middle aged men in Shanghai, China. BMJ 1997; 314:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/33\">",
"      Laporte RE, Cresanta JL, Kuller LH. The relation of alcohol to coronary heart disease and mortality: implications for public health policy. J Public Health Policy 1980; 1:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/34\">",
"      Doll R, Peto R, Hall E, et al. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ 1994; 309:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/35\">",
"      Palmer AJ, Fletcher AE, Bulpitt CJ, et al. Alcohol intake and cardiovascular mortality in hypertensive patients: report from the Department of Health Hypertension Care Computing Project. J Hypertens 1995; 13:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/36\">",
"      Malinski MK, Sesso HD, Lopez-Jimenez F, et al. Alcohol consumption and cardiovascular disease mortality in hypertensive men. Arch Intern Med 2004; 164:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/37\">",
"      Hvidtfeldt UA, Tolstrup JS, Jakobsen MU, et al. Alcohol intake and risk of coronary heart disease in younger, middle-aged, and older adults. Circulation 2010; 121:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/38\">",
"      Hein HO, S&oslash;rensen H, Suadicani P, Gyntelberg F. Alcohol consumption, Lewis phenotypes, and risk of ischaemic heart disease. Lancet 1993; 341:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/39\">",
"      Djouss&eacute; L, Karamohamed S, Herbert AG, et al. Fucosyltransferase 3 polymorphism and atherothrombotic disease in the Framingham Offspring Study. Am Heart J 2007; 153:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/40\">",
"      Hein HO, Suadicani P, Gyntelberg F. Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: six year follow up in the Copenhagen male study. BMJ 1996; 312:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/41\">",
"      Hines LM, Stampfer MJ, Ma J, et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med 2001; 344:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/42\">",
"      Djouss&eacute; L, Levy D, Herbert AG, et al. Influence of alcohol dehydrogenase 1C polymorphism on the alcohol-cardiovascular disease association (from the Framingham Offspring Study). Am J Cardiol 2005; 96:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/43\">",
"      Zee RY, Ridker PM, Cook NR. Prospective evaluation of the alcohol dehydrogenase gamma1/gamma2 gene polymorphism and risk of stroke. Stroke 2004; 35:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/44\">",
"      Mukamal KJ, Cushman M, Mittleman MA, et al. Alcohol consumption and inflammatory markers in older adults: the Cardiovascular Health Study. Atherosclerosis 2004; 173:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/45\">",
"      Mukamal KJ, Kuller LH, Fitzpatrick AL, et al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003; 289:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/46\">",
"      Mukamal KJ, Chung H, Jenny NS, et al. Alcohol use and risk of ischemic stroke among older adults: the cardiovascular health study. Stroke 2005; 36:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/47\">",
"      Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/48\">",
"      Carnacini A, Arfelli G. Selected nutritional components of wine. Alcologia 1994; 6:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/49\">",
"      Waddington E, Puddey IB, Croft KD. Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation. Am J Clin Nutr 2004; 79:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/50\">",
"      Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 2007; 28:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/51\">",
"      Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ 1996; 312:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/52\">",
"      Keil U, Chambless LE, D&ouml;ring A, et al. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. Epidemiology 1997; 8:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/53\">",
"      Marques-Vidal P, Ducimeti&egrave;re P, Evans A, et al. Alcohol consumption and myocardial infarction: a case-control study in France and Northern Ireland. Am J Epidemiol 1996; 143:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/54\">",
"      Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/55\">",
"      Mackenbach JP, van den Bos J, Joung IM, et al. The determinants of excellent health: different from the determinants of ill-health? Int J Epidemiol 1994; 23:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/56\">",
"      Poikolainen K, Vartiainen E, Korhonen HJ. Alcohol intake and subjective health. Am J Epidemiol 1996; 144:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/57\">",
"      Marmot MG, North F, Feeney A, Head J. Alcohol consumption and sickness absence: from the Whitehall II study. Addiction 1993; 88:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/58\">",
"      Karlamangla AS, Sarkisian CA, Kado DM, et al. Light to moderate alcohol consumption and disability: variable benefits by health status. Am J Epidemiol 2009; 169:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/59\">",
"      Jin M, Cai S, Guo J, et al. Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol 2013; 24:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/60\">",
"      Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001; 286:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/61\">",
"      Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 2009; 101:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/62\">",
"      Chen WY, Rosner B, Hankinson SE, et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011; 306:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/63\">",
"      Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013; 24:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/64\">",
"      Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/65\">",
"      Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007; 165:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/66\">",
"      Tseng M, Weinberg CR, Umbach DM, Longnecker MP. Calculation of population attributable risk for alcohol and breast cancer (United States). Cancer Causes Control 1999; 10:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/67\">",
"      Mezzetti M, La Vecchia C, Decarli A, et al. Population attributable risk for breast cancer: diet, nutrition, and physical exercise. J Natl Cancer Inst 1998; 90:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/68\">",
"      Sch&uuml;tze M, Boeing H, Pischon T, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011; 342:d1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/69\">",
"      Chen WY, Colditz GA, Rosner B, et al. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med 2002; 137:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/70\">",
"      Li CI, Malone KE, Porter PL, et al. The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. Cancer Epidemiol Biomarkers Prev 2003; 12:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/71\">",
"      Suzuki R, Ye W, Rylander-Rudqvist T, et al. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005; 97:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/72\">",
"      Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/73\">",
"      Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/74\">",
"      Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 2001; 12:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/75\">",
"      Sellers TA, Vierkant RA, Cerhan JR, et al. Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002; 11:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/76\">",
"      Choumenkovitch SF, Selhub J, Wilson PW, et al. Folic acid intake from fortification in United States exceeds predictions. J Nutr 2002; 132:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/77\">",
"      Sabroe S. Alcohol and cancer. Still no clear evidence to link specific beverages to specific cancers. BMJ 1998; 317:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/78\">",
"      Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001; 85:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/79\">",
"      Rehm J, Patra J, Popova S. Alcohol drinking cessation and its effect on esophageal and head and neck cancers: a pooled analysis. Int J Cancer 2007; 121:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/80\">",
"      Winn DM, Blot WJ, McLaughlin JK, et al. Mouthwash use and oral conditions in the risk of oral and pharyngeal cancer. Cancer Res 1991; 51:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/81\">",
"      Cole P, Rodu B, Mathisen A. Alcohol-containing mouthwash and oropharyngeal cancer: a review of the epidemiology. J Am Dent Assoc 2003; 134:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/82\">",
"      Choi SY, Kahyo H. Effect of cigarette smoking and alcohol consumption in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Epidemiol 1991; 20:878.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson P. Alcohol and risk of physical harm. In: Alcohol and Public Policy: Evidence and Issues, Holder HD, Edwards G (Eds), Oxford University Press, New York 1995. p.82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/84\">",
"      Pandeya N, Williams G, Green AC, et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009; 136:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/85\">",
"      Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009; 136:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/86\">",
"      Longnecker MP, Orza MJ, Adams ME, et al. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer. Cancer Causes Control 1990; 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/87\">",
"      Gapstur SM, Potter JD, Folsom AR. Alcohol consumption and colon and rectal cancer in postmenopausal women. Int J Epidemiol 1994; 23:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/88\">",
"      Shimizu N, Nagata C, Shimizu H, et al. Height, weight, and alcohol consumption in relation to the risk of colorectal cancer in Japan: a prospective study. Br J Cancer 2003; 88:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/89\">",
"      Ye W, Romelsj&ouml; A, Augustsson K, et al. No excess risk of colorectal cancer among alcoholics followed for up to 25 years. Br J Cancer 2003; 88:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/90\">",
"      Adami HO, McLaughlin JK, Hsing AW, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control 1992; 3:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/91\">",
"      Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/92\">",
"      Pedersen A, Johansen C, Gr&oslash;nbaek M. Relations between amount and type of alcohol and colon and rectal cancer in a Danish population based cohort study. Gut 2003; 52:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/93\">",
"      Harnack L, Jacobs DR Jr, Nicodemus K, et al. Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutr Cancer 2002; 43:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/94\">",
"      Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995; 87:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/95\">",
"      Harnack LJ, Anderson KE, Zheng W, et al. Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 1997; 6:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/96\">",
"      Tavani A, Pregnolato A, Negri E, La Vecchia C. Alcohol consumption and risk of pancreatic cancer. Nutr Cancer 1997; 27:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/97\">",
"      Lee CT, Chang FY, Lee SD. Risk factors for pancreatic cancer in orientals. J Gastroenterol Hepatol 1996; 11:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/98\">",
"      Ji BT, Chow WH, Dai Q, et al. Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a case-control study in Shanghai, China. Cancer Causes Control 1995; 6:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/99\">",
"      Rohrmann S, Linseisen J, Vrieling A, et al. Ethanol intake and the risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2009; 20:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/100\">",
"      Silverman DT, Brown LM, Hoover RN, et al. Alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res 1995; 55:4899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/101\">",
"      Partanen TJ, Vainio HU, Ojaj&auml;rvi IA, Kauppinen TP. Pancreas cancer, tobacco smoking and consumption of alcoholic beverages: a case-control study. Cancer Lett 1997; 116:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/102\">",
"      Tagger A, Donato F, Ribero ML, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/103\">",
"      Marsano LS, Pe&ntilde;a LR. The interaction of alcoholic liver disease and hepatitis C. Hepatogastroenterology 1998; 45:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/104\">",
"      Trichopoulos D, Day NE, Kaklamani E, et al. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987; 39:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/105\">",
"      Mohamed AE, Kew MC, Groeneveld HT. Alcohol consumption as a risk factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/106\">",
"      Tanaka K, Hirohata T, Takeshita S, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: a case-control study in Fukuoka, Japan. Int J Cancer 1992; 51:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/107\">",
"      Djouss&eacute; L, Dorgan JF, Zhang Y, et al. Alcohol consumption and risk of lung cancer: the Framingham Study. J Natl Cancer Inst 2002; 94:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/108\">",
"      Korte JE, Brennan P, Henley SJ, Boffetta P. Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. Am J Epidemiol 2002; 155:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/109\">",
"      Ohta S, Watanabe Y, Nakajima T. Consumption of alcohol in the presence of hepatitis C virus is an additive risk for liver damage. Prev Med 1998; 27:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/110\">",
"      Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/111\">",
"      Sachithanandan S, Kay E, Leader M, Fielding JF. The effect of light drinking on HCV liver disease: the jury is still out. Biomed Pharmacother 1997; 51:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/112\">",
"      Mochida S, Ohnishi K, Matsuo S, et al. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996; 20:371A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/113\">",
"      Maclure KM, Hayes KC, Colditz GA, et al. Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med 1989; 321:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/114\">",
"      Grodstein F, Colditz GA, Hunter DJ, et al. A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors. Obstet Gynecol 1994; 84:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/115\">",
"      Mart&iacute;nez de Pancorbo C, Carballo F, Horcajo P, et al. Prevalence and associated factors for gallstone disease: results of a population survey in Spain. J Clin Epidemiol 1997; 50:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/116\">",
"      Attili AF, Scafato E, Marchioli R, et al. Diet and gallstones in Italy: the cross-sectional MICOL results. Hepatology 1998; 27:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/117\">",
"      Moro PL, Checkley W, Gilman RH, et al. Gallstone disease in high-altitude Peruvian rural populations. Am J Gastroenterol 1999; 94:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/118\">",
"      Caroli-Bosc FX, Deveau C, Peten EP, et al. Cholelithiasis and dietary risk factors: an epidemiologic investigation in Vidauban, Southeast France. General Practitioner's Group of Vidauban. Dig Dis Sci 1998; 43:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/119\">",
"      Schwesinger WH, Kurtin WE, Johnson R. Alcohol protects against cholesterol gallstone formation. Ann Surg 1988; 207:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/120\">",
"      Poynard T, Lonjon I, Mathurin P, et al. Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. Alcohol Clin Exp Res 1995; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     Babor TF, Kranzler HR, Lauerman RJ. Social drinking as a health and psychosocial risk factor. In: Recent Developments in Alcoholism, Galanter M (Ed), Plenum, New York 1987. p.373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/122\">",
"      Durbec JP, Sarles H. Multicenter survey of the etiology of pancreatic diseases. Relationship between the relative risk of developing chronic pancreaitis and alcohol, protein and lipid consumption. Digestion 1978; 18:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/123\">",
"      Kristiansen L, Gr&oslash;nbaek M, Becker U, Tolstrup JS. Risk of pancreatitis according to alcohol drinking habits: a population-based cohort study. Am J Epidemiol 2008; 168:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/124\">",
"      Schaeffner ES, Kurth T, de Jong PE, et al. Alcohol consumption and the risk of renal dysfunction in apparently healthy men. Arch Intern Med 2005; 165:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/125\">",
"      Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/126\">",
"      Vupputuri S, Sandler DP. Lifestyle risk factors and chronic kidney disease. Ann Epidemiol 2003; 13:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/127\">",
"      Bikle DD, Genant HK, Cann C, et al. Bone disease in alcohol abuse. Ann Intern Med 1985; 103:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/128\">",
"      Israel Y, Orrego H, Holt S, et al. Identification of alcohol abuse: thoracic fractures on routine chest X-rays as indicators of alcoholism. Alcohol Clin Exp Res 1980; 4:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/129\">",
"      Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1996; 124:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/130\">",
"      Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995; 142:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/131\">",
"      Patton CL, Millard PS, Kessenich CR, et al. Screening calcaneal ultrasound and risk factors for osteoporosis among lesbians and heterosexual women. J Womens Health 1998; 7:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/132\">",
"      Smeets-Goevaers CG, Lesusink GL, Papapoulos SE, et al. The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study. Osteoporos Int 1998; 8:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/133\">",
"      Hansen MA, Overgaard K, Riis BJ, Christiansen C. Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int 1991; 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/134\">",
"      Gavaler JS, Love K, Van Thiel D, et al. An international study of the relationship between alcohol consumption and postmenopausal estradiol levels. Alcohol Alcohol Suppl 1991; 1:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/135\">",
"      Hernandez-Avila M, Colditz GA, Stampfer MJ, et al. Caffeine, moderate alcohol intake, and risk of fractures of the hip and forearm in middle-aged women. Am J Clin Nutr 1991; 54:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/136\">",
"      Clark P, de la Pe&ntilde;a F, G&oacute;mez Garc&iacute;a F, et al. Risk factors for osteoporotic hip fractures in Mexicans. Arch Med Res 1998; 29:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/137\">",
"      Hemenway D, Colditz GA, Willett WC, et al. Fractures and lifestyle: effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women. Am J Public Health 1988; 78:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/138\">",
"      Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 1995; 10:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/139\">",
"      Suzuki T, Yoshida H, Hashimoto T, et al. Case-control study of risk factors for hip fractures in the Japanese elderly by a Mediterranean Osteoporosis Study (MEDOS) questionnaire. Bone 1997; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/140\">",
"      Naves Diaz M, O'Neill TW, Silman AJ. The influence of alcohol consumption on the risk of vertebral deformity. European Vertebral Osteoporosis Study Group. Osteoporos Int 1997; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/141\">",
"      Turner LW, Wang MQ, Fu Q. Risk factors for hip fracture among southern older women. South Med J 1998; 91:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/142\">",
"      Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 2008; 121:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/143\">",
"      Mukamal KJ, Mittleman MA, Longstreth WT Jr, et al. Self-reported alcohol consumption and falls in older adults: cross-sectional and longitudinal analyses of the cardiovascular health study. J Am Geriatr Soc 2004; 52:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/144\">",
"      Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004; 140:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/145\">",
"      Koppes LL, Dekker JM, Hendriks HF, et al. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 2005; 28:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/146\">",
"      Rimm EB, Chan J, Stampfer MJ, et al. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ 1995; 310:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/147\">",
"      Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol 1988; 128:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/148\">",
"      Kiechl S, Willeit J, Poewe W, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ 1996; 313:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/149\">",
"      Mayer EJ, Newman B, Quesenberry CP Jr, et al. Alcohol consumption and insulin concentrations. Role of insulin in associations of alcohol intake with high-density lipoprotein cholesterol and triglycerides. Circulation 1993; 88:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/150\">",
"      Razay G, Heaton KW, Bolton CH, Hughes AO. Alcohol consumption and its relation to cardiovascular risk factors in British women. BMJ 1992; 304:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/151\">",
"      Bell RA, Mayer-Davis EJ, Martin MA, et al. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care 2000; 23:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/152\">",
"      Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/153\">",
"      Wannamethee SG, Camargo CA Jr, Manson JE, et al. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch Intern Med 2003; 163:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/154\">",
"      Davies MJ, Baer DJ, Judd JT, et al. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 2002; 287:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/155\">",
"      Shai I, Wainstein J, Harman-Boehm I, et al. Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. Diabetes Care 2007; 30:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/156\">",
"      Marfella R, Cacciapuoti F, Siniscalchi M, et al. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. Diabet Med 2006; 23:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/157\">",
"      Brand-Miller JC, Fatema K, Fatima K, et al. Effect of alcoholic beverages on postprandial glycemia and insulinemia in lean, young, healthy adults. Am J Clin Nutr 2007; 85:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/158\">",
"      Satoh H, Nguyen MT, Trujillo M, et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005; 54:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/159\">",
"      Sierksma A, Patel H, Ouchi N, et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 2004; 27:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/160\">",
"      Pischon T, Girman CJ, Rifai N, et al. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 2005; 81:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/161\">",
"      Valmadrid CT, Klein R, Moss SE, et al. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999; 282:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/162\">",
"      McCulloch DK, Campbell IW, Prescott RJ, Clarke BF. Effect of alcohol intake on symptomatic peripheral neuropathy in diabetic men. Diabetes Care 1980; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/163\">",
"      O'Keefe SJ, Marks V. Lunchtime gin and tonic a cause of reactive hypoglycaemia. Lancet 1977; 1:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/164\">",
"      Richardson T, Weiss M, Thomas P, Kerr D. Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes. Diabetes Care 2005; 28:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/165\">",
"      Sokol RJ, Clarren SK. Guidelines for use of terminology describing the impact of prenatal alcohol on the offspring. Alcohol Clin Exp Res 1989; 13:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/166\">",
"      Ernhart CB, Sokol RJ, Martier S, et al. Alcohol teratogenicity in the human: a detailed assessment of specificity, critical period, and threshold. Am J Obstet Gynecol 1987; 156:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/167\">",
"      Mart&iacute;nez-Fr&iacute;as ML, Bermejo E, Rodr&iacute;guez-Pinilla E, Fr&iacute;as JL. Risk for congenital anomalies associated with different sporadic and daily doses of alcohol consumption during pregnancy: a case-control study. Birth Defects Res A Clin Mol Teratol 2004; 70:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/168\">",
"      Tittmar HG. What's the harm in just a drink? Alcohol Alcohol 1990; 25:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/169\">",
"      Polygenis D, Wharton S, Malmberg C, et al. Moderate alcohol consumption during pregnancy and the incidence of fetal malformations: a meta-analysis. Neurotoxicol Teratol 1998; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/170\">",
"      Abel EL. \"Moderate\" drinking during pregnancy: cause for concern? Clin Chim Acta 1996; 246:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/171\">",
"      Blume SB. Is social drinking during pregnancy harmless? There is reason to think not. Adv Alcohol Subst Abuse 1985; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/172\">",
"      Harlap S, Shiono PH. Alcohol, smoking, and incidence of spontaneous abortions in the first and second trimester. Lancet 1980; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/173\">",
"      Windham GC, Von Behren J, Fenster L, et al. Moderate maternal alcohol consumption and risk of spontaneous abortion. Epidemiology 1997; 8:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/174\">",
"      Abel EL. Maternal alcohol consumption and spontaneous abortion. Alcohol Alcohol 1997; 32:211.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute of Alcohol Abuse and Alcoholism. Drinking and your pregnancy. National Institute of Health; US Department of Health and Human Services, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/176\">",
"      Vinson DC, Mabe N, Leonard LL, et al. Alcohol and injury. A case-crossover study. Arch Fam Med 1995; 4:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/177\">",
"      Voas RB. Issues in cross-national comparisons of crash data. Addiction 1993; 88:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/178\">",
"      LOOMIS TA, WEST TC. The influence of alcohol on automobile driving ability; an experimental study for the evaluation of certain medicological aspects. Q J Stud Alcohol 1958; 19:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/179\">",
"      H&iacute;jar M, Flores M, L&oacute;pez MV, Rosovsky H. Alcohol intake and severity of injuries on highways in Mexico: a comparative analysis. Addiction 1998; 93:1543.",
"     </a>",
"    </li>",
"    <li>",
"     Asch T, Levy D. The minimum legal drinking age and traffic fatalities. Rutgers University, NIAAA 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/181\">",
"      Morrow D, Leirer V, Yesavage J, Tinklenberg J. Alcohol, age, and piloting: judgement, mood, and actual performance. Int J Addict 1991; 26:669.",
"     </a>",
"    </li>",
"    <li>",
"     Mengert, P, Sussman, ED, DiSario, R. A study of the relationship between the risk of fatality and blood alcohol concentration of recreational boat operators. Report CG-D-09-92. U.S. Coast Guard, Washington DC 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/183\">",
"      Olkkonen S, Honkanen R. The role of alcohol in nonfatal bicycle injuries. Accid Anal Prev 1990; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/184\">",
"      Li G, Baker SP, Smialek JE, Soderstrom CA. Use of alcohol as a risk factor for bicycling injury. JAMA 2001; 285:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/185\">",
"      Waller J, Lamborn K. Snowmobiling: Characteristics of owners, patterns of use and injuries. Accid Anal Prev 1975; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     Romelsjo A. Alcohol consumption and unintentional injury, suicide, violence, work performance, and inter-generational effects. In: Alcohol and Public Policy: Evidence and Issues, Holder HD, Edwards G (Eds), Oxford University Press, New York 1995. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/187\">",
"      Martin SE. The epidemiology of alcohol-related interpersonal violence. Alcohol Health Res World 1992; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/188\">",
"      Cherpitel CJ, Tam T, Midanik L, et al. Alcohol and non-fatal injury in the U.S. general population: a risk function analysis. Accid Anal Prev 1995; 27:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/189\">",
"      Hall RC, Platt DE, Hall RC. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics 1999; 40:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/190\">",
"      Berglund M, Ojehagen A. The influence of alcohol drinking and alcohol use disorders on psychiatric disorders and suicidal behavior. Alcohol Clin Exp Res 1998; 22:333S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/191\">",
"      Klatsky AL, Armstrong MA. Alcohol use, other traits, and risk of unnatural death: a prospective study. Alcohol Clin Exp Res 1993; 17:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/192\">",
"      Andreasson S, Allebeck P, Romelsj&ouml; A. Alcohol and mortality among young men: longitudinal study of Swedish conscripts. Br Med J (Clin Res Ed) 1988; 296:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/193\">",
"      Mukamal KJ, Kawachi I, Miller M, Rimm EB. Drinking frequency and quantity and risk of suicide among men. Soc Psychiatry Psychiatr Epidemiol 2007; 42:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/194\">",
"      Murphy GE, Wetzel RD. The lifetime risk of suicide in alcoholism. Arch Gen Psychiatry 1990; 47:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/195\">",
"      Borges G, Cherpitel CJ, MacDonald S, et al. A case-crossover study of acute alcohol use and suicide attempt. J Stud Alcohol 2004; 65:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/196\">",
"      Broe GA, Creasey H, Jorm AF, et al. Health habits and risk of cognitive impairment and dementia in old age: a prospective study on the effects of exercise, smoking and alcohol consumption. Aust N Z J Public Health 1998; 22:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/197\">",
"      Hebert LE, Scherr PA, Beckett LA, et al. Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am J Epidemiol 1992; 135:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/198\">",
"      Graves AB, van Duijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991; 20 Suppl 2:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/199\">",
"      Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/200\">",
"      Ruitenberg A, van Swieten JC, Witteman JC, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002; 359:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/201\">",
"      Ganguli M, Vander Bilt J, Saxton JA, et al. Alcohol consumption and cognitive function in late life: a longitudinal community study. Neurology 2005; 65:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/202\">",
"      Stampfer MJ, Kang JH, Chen J, et al. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 2005; 352:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/203\">",
"      Wright CB, Elkind MS, Rundek T, et al. Alcohol intake, carotid plaque, and cognition: the Northern Manhattan Study. Stroke 2006; 37:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/204\">",
"      Stott DJ, Falconer A, Kerr GD, et al. Does low to moderate alcohol intake protect against cognitive decline in older people? J Am Geriatr Soc 2008; 56:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/205\">",
"      Cooper C, Bebbington P, Meltzer H, et al. Alcohol in moderation, premorbid intelligence and cognition in older adults: results from the Psychiatric Morbidity Survey. J Neurol Neurosurg Psychiatry 2009; 80:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/206\">",
"      Luchsinger JA, Tang MX, Siddiqui M, et al. Alcohol intake and risk of dementia. J Am Geriatr Soc 2004; 52:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/207\">",
"      Mehlig K, Skoog I, Guo X, et al. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Goteborg. Am J Epidemiol 2008; 167:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/208\">",
"      Anttila T, Helkala EL, Viitanen M, et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 2004; 329:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/209\">",
"      Evans DA, Bienias JL. Alcohol consumption and cognition. N Engl J Med 2005; 352:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/61/38874/abstract/210\">",
"      Romelsj&ouml; A, Leifman A. Association between alcohol consumption and mortality, myocardial infarction, and stroke in 25 year follow up of 49 618 young Swedish men. BMJ 1999; 319:821.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2781 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38874=[""].join("\n");
var outline_f37_61_38874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PITFALLS IN STUDIES OF ALCOHOL CONSUMPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS AND THE \"IDEAL DOSE\" OF ALCOHOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H159190429\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H159190596\">",
"      The \"ideal dose\" of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALCOHOL AND TOTAL MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Beverage types",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Resveratrol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H739563958\">",
"      ALCOHOL AND OVERALL HEALTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALCOHOL AND SPECIFIC ILLNESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4656216\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Oral cavity, larynx, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Esophageal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Colorectal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pancreatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatocellular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonmalignant liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cholelithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Accidents and trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2781|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/18/20778\" title=\"figure 1\">",
"      Standard alcoholic drink PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/32/27150\" title=\"figure 2\">",
"      Alcohol consumption mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/63/21490\" title=\"figure 3\">",
"      Alcohol impairment chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/3/1073\" title=\"table 1\">",
"      World recs alcohol consump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/41/29339\" title=\"table 2\">",
"      Fetal alcohol syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18696?source=related_link\">",
"      Community violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9496?source=related_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_61_38875="Young and Burgess classification of pelvic fractures";
var content_f37_61_38875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Young and Burgess classification of pelvic fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        LC: anterior injury = rami fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LC I: sacral fracture on side of impact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LC II: crescent fracture on side of impact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LC III: type I or II injury on side of impact with contralateral open book injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        AP compression (APC): anterior injury = symphysis diastasis/rami fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        APC I: minor opening of symphysis and SI joint anteriorly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        APC II: opening of anterior SI, intact posterior SI ligaments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        APC III: complete disruption of SI joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Vertical shear (VS) type:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertical displacement of hemipelvis with symphysis diastasis or rami fractures anteriorly, iliac wing, sacral facture, or SI dislocation posteriorly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Combined mechanism (CM) type: any combination of above injuries",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38875=[""].join("\n");
var outline_f37_61_38875=null;
var title_f37_61_38876="Congenital syphilis case definition-CDC";
var content_f37_61_38876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    US Centers for Disease Control and Prevention (CDC) surveillance case definition for congenital syphilis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory criteria for diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of",
"        <em>",
"         Treponema pallidum",
"        </em>",
"        by darkfield microscopy, fluorescent antibody, or other specific stains in specimens from lesions, placenta, umbilical cord, or autopsy material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Case classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infant whose mother had untreated or inadequately",
"        <sup>",
"         &bull;",
"        </sup>",
"        treated syphilis at delivery, regardless of signs in the infant, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Infant or child who has a reactive treponemal test for syphilis and any one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        - Any evidence of congenital syphilis on physical examination:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        For children 0 to 2 years: Hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice, pseudoparalysis, edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        For children &gt;2 years: Interstitial keratitis, sensorineural hearing loss, \"saber shins\"",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , frontal bossing, Hutchinson teeth",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , mulberry molars",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , saddle nose, rhagades",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Clutton joints",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - Any evidence of congenital syphilis on radiographs of long bones",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - A reactive cerebrospinal fluid (CSF) venereal disease research laboratory (VDRL) test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - An elevated CSF cell count or protein (without other cause)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Confirmed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Case that is laboratory confirmed",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For reporting purposes, congenital syphilis includes cases of congenitally acquired syphilis among infants and children, as well as syphilitic stillbirths (death of a fetus weighing &gt;500 g or having a gestational age &gt;20 weeks in which the mother had untreated or inadequately treated syphilis at delivery).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      For the purpose of the CDC case definition, inadequate treatment is defined by any non-penicillin therapy or any therapy (including penicillin) given less than 30 days before delivery. Other definitions of inadequate treatment may also include undocumented therapy, subtherapeutic or undocumented treatment response, and inappropriate dose for maternal stage of disease.",
"      <br>",
"       &Delta; See text of topic for description.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Centers for Disease Control and Prevention. Congenital syphilis (Treponema pallidum) case definition, 1996.",
"     <a href=\"file://www.cdc.gov/ncphi/od/ai/casedef/syphilisccurrent.htm\">",
"      file://www.cdc.gov/ncphi/od/ai/casedef/syphilisccurrent.htm",
"     </a>",
"     . (Accessed on September 30, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38876=[""].join("\n");
var outline_f37_61_38876=null;
var title_f37_61_38877="Digoxin and HF mortality";
var content_f37_61_38877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digoxin reduces death and hospitalization due to worsening HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 6800 patients with heart failure randomized to therapy with digoxin or placebo, patients treated with digoxin had a significant decrease in the combined endpoints of death from HF and hospitalization for worsening HF (p&lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The Digitalis Investigation Group, N Engl J Med 1997; 336:525.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38877=[""].join("\n");
var outline_f37_61_38877=null;
var title_f37_61_38878="Lymphoma bone Xray";
var content_f37_61_38878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoma of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral plain film of the knee demonstrates a \"moth-eaten\" pattern in the proximal tibia at the metadiaphyseal junction, along with bone destruction (large arrow). An associated periosteal reaction is present (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heather Pacholke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38878=[""].join("\n");
var outline_f37_61_38878=null;
var title_f37_61_38879="IVP in papillary necrosis";
var content_f37_61_38879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic representation of radiographic findings by IVP in patients with papillary necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the radiographic findings (on intravenous or retrograde pyelography) that may be present in papillary necrosis (PN). Partial PN (left) is characterized by partial sloughing of the papilla, producing a small and a large cavity extending out from the lower two calyces (arrows). The upper calyx shows a medullary ring in which part of the sloughed papilla has remained in place. In complete PN (right), the entire papillary surface is lost as in the lower calyx. A ring shadow is present in the middle calyx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Harrow, BR, Sloane, JA, Liebman, NC, JAMA 1963; 184:445. By permission of the American Medical Association, copyright 1963.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_61_38879=[""].join("\n");
var outline_f37_61_38879=null;
